<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Med Virol</journal-id><journal-id journal-id-type="iso-abbrev">Rev Med Virol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1099-1654</journal-id><journal-id journal-id-type="publisher-id">RMV</journal-id><journal-title-group><journal-title>Reviews in Medical Virology</journal-title></journal-title-group><issn pub-type="ppub">1052-9276</issn><issn pub-type="epub">1099-1654</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7536932</article-id><article-id pub-id-type="doi">10.1002/rmv.2163</article-id><article-id pub-id-type="publisher-id">RMV2163</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Reviews</subject></subj-group></article-categories><title-group><article-title>Azithromycin in viral infections</article-title><alt-title alt-title-type="left-running-head">Oliver and Hinks</alt-title></title-group><contrib-group><contrib id="rmv2163-cr-0001" contrib-type="author"><name><surname>Oliver</surname><given-names>Madeleine E.</given-names></name><xref ref-type="aff" rid="rmv2163-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="rmv2163-cr-0002" contrib-type="author" corresp="yes"><name><surname>Hinks</surname><given-names>Timothy S. C.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0699-2373</contrib-id><xref ref-type="aff" rid="rmv2163-aff-0002">
<sup>2</sup>
</xref><address><email>timothy.hinks@ndm.ox.ac.uk</email></address></contrib></contrib-group><aff id="rmv2163-aff-0001">
<label><sup>1</sup></label>
<institution>New College, University of Oxford</institution>
<city>Oxford</city>
<country country="GB">UK</country>
</aff><aff id="rmv2163-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Nuffield Department of Medicine Experimental Medicine, Respiratory Medicine Unit and National Institute for Health Research (NIHR), Oxford Biomedical Research Centre (BRC)</named-content>
<institution>University of Oxford</institution>
<city>Oxford</city>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Timothy S. C. Hinks, Nuffield Department of Medicine Experimental Medicine, Respiratory Medicine Unit and National Institute for Health Research (NIHR), Oxford Biomedical Research Centre (BRC), University of Oxford, Level 5, John Radcliffe Hospital, Oxford OX3 9DU, UK.<break/>
Email: <email>timothy.hinks@ndm.ox.ac.uk</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>9</month><year>2020</year></pub-date><elocation-id>e2163</elocation-id><history><date date-type="received"><day>30</day><month>7</month><year>2020</year></date><date date-type="rev-recd"><day>19</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>20</day><month>8</month><year>2020</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 John Wiley & Sons, Ltd. <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2020 The Authors. <italic>Reviews in Medical Virology</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:RMV-9999-e2163.pdf"/><abstract><title>Summary</title><p>Azithromycin (AZM) is a synthetic macrolide antibiotic effective against a broad range of bacterial and mycobacterial infections. Due to an additional range of anti&#x02010;viral and anti&#x02010;inflammatory properties, it has been given to patients with the coronaviruses SARS&#x02010;CoV or MERS&#x02010;CoV. It is now being investigated as a potential candidate treatment for SARS&#x02010;CoV&#x02010;2 having been identified as a candidate therapeutic for this virus by both in vitro and in silico drug screens. To date there are no randomised trial data on its use in any novel coronavirus infection, although a large number of trials are currently in progress. In this review, we summarise data from in vitro, murine and human clinical studies on the anti&#x02010;viral and anti&#x02010;inflammatory properties of macrolides, particularly AZM. AZM reduces in vitro replication of several classes of viruses including rhinovirus, influenza A, Zika virus, Ebola, enteroviruses and coronaviruses, via several mechanisms. AZM enhances expression of anti&#x02010;viral pattern recognition receptors and induction of anti&#x02010;viral type I and III interferon responses. Of relevance to severe coronavirus&#x02010;19 disease (COVID&#x02010;19), which is characterised by an over&#x02010;exuberant innate inflammatory response, AZM also has anti&#x02010;inflammatory properties including suppression of IL&#x02010;1beta, IL&#x02010;2, TNF and GM&#x02010;CSF. AZM inhibits T cells by inhibiting calcineurin signalling, mammalian target of rapamycin activity and NF&#x003ba;B activation. AZM particularly targets granulocytes where it concentrates markedly in lysosomes, particularly affecting accumulation, adhesion, degranulation and apoptosis of neutrophils. Given its proven safety, affordability and global availability, tempered by significant concerns about antimicrobial stewardship, there is an urgent mandate to perform well&#x02010;designed and conducted randomised clinical trials.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="rmv2163-kwd-0001">azithromycin</kwd><kwd id="rmv2163-kwd-0002">coronavirus</kwd><kwd id="rmv2163-kwd-0003">COVID&#x02010;19</kwd><kwd id="rmv2163-kwd-0004">macrolide</kwd><kwd id="rmv2163-kwd-0005">mechanism</kwd><kwd id="rmv2163-kwd-0006">review</kwd><kwd id="rmv2163-kwd-0007">SARS&#x02010;CoV&#x02010;2</kwd><kwd id="rmv2163-kwd-0008">virus</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>University of Oxford </institution><institution-id institution-id-type="open-funder-registry">10.13039/501100000769</institution-id></institution-wrap></funding-source><award-id>University of Oxford COVID&#x02010;19 Research Response Fund</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Wellcome Trust </institution><institution-id institution-id-type="open-funder-registry">10.13039/100010269</institution-id></institution-wrap></funding-source><award-id>211050/Z/18/A</award-id><award-id>211050/Z/18/z</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Pfizer </institution><institution-id institution-id-type="open-funder-registry">10.13039/100004319</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0004"><funding-source>National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="2"/><page-count count="13"/><word-count count="11102"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.2 mode:remove_FC converted:06.10.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="rmv2163-cit-9001">
<string-name>
<surname>Oliver</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Hinks</surname>
<given-names>TSC</given-names>
</string-name>. <article-title>Azithromycin in viral infections</article-title>. <source xml:lang="en">Rev Med Virol</source>. <year>2020</year>;<elocation-id>e2163</elocation-id>
<pub-id pub-id-type="doi">10.1002/rmv.2163</pub-id>
<pub-id pub-id-type="pmid">32969125</pub-id></mixed-citation>
</p><fn-group><fn id="rmv2163-note-1002"><p>
<bold>Funding information</bold> University of Oxford, Grant/Award Number: University of Oxford COVID&#x02010;19 Research Response Fund; Wellcome Trust, Grant/Award Numbers: 211050/Z/18/A, 211050/Z/18/z; Pfizer; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)</p></fn></fn-group></notes></front><body id="rmv2163-body-0001"><def-list list-content="abbreviations" id="rmv2163-lp-0001"><title>Abbreviations</title><def-item><term id="rmv2163-li-0001">AZM</term><def id="rmv2163-li-0002"><p>azithromycin</p></def></def-item><def-item><term id="rmv2163-li-0003">CAP</term><def id="rmv2163-li-0004"><p>community acquired pneumonia</p></def></def-item><def-item><term id="rmv2163-li-0005">CCL</term><def id="rmv2163-li-0006"><p>C&#x02010;C motif ligand</p></def></def-item><def-item><term id="rmv2163-li-0007">CD</term><def id="rmv2163-li-0008"><p>cluster of differentiation</p></def></def-item><def-item><term id="rmv2163-li-0009">CF</term><def id="rmv2163-li-0010"><p>cystic fibrosis</p></def></def-item><def-item><term id="rmv2163-li-0011">COVID&#x02010;19</term><def id="rmv2163-li-0012"><p>coronavirus&#x02010;19 disease</p></def></def-item><def-item><term id="rmv2163-li-0013">COX</term><def id="rmv2163-li-0014"><p>cyclooxygenase</p></def></def-item><def-item><term id="rmv2163-li-0015">cPLA2</term><def id="rmv2163-li-0016"><p>cytosolic phospholipase A2</p></def></def-item><def-item><term id="rmv2163-li-0017">CRP</term><def id="rmv2163-li-0018"><p>C&#x02010;reactive protein</p></def></def-item><def-item><term id="rmv2163-li-0019">CXCL</term><def id="rmv2163-li-0020"><p>C&#x02010;X&#x02010;C motif ligand</p></def></def-item><def-item><term id="rmv2163-li-0021">DPB</term><def id="rmv2163-li-0022"><p>diffuse panbronchiolitis</p></def></def-item><def-item><term id="rmv2163-li-0023">ERK</term><def id="rmv2163-li-0024"><p>extracellular signal&#x02010;regulated kinase</p></def></def-item><def-item><term id="rmv2163-li-0025">GM&#x02010;CSF</term><def id="rmv2163-li-0026"><p>granulocyte&#x02010;macrophage colony&#x02010;stimulating factor (CSF2)</p></def></def-item><def-item><term id="rmv2163-li-0027">HCQ</term><def id="rmv2163-li-0028"><p>hydroxychloroquine</p></def></def-item><def-item><term id="rmv2163-li-0029">hPSC</term><def id="rmv2163-li-0030"><p>human pluripotent stem cell</p></def></def-item><def-item><term id="rmv2163-li-0031">ICU</term><def id="rmv2163-li-0032"><p>intensive care unit</p></def></def-item><def-item><term id="rmv2163-li-0033">IL</term><def id="rmv2163-li-0034"><p>interleukin</p></def></def-item><def-item><term id="rmv2163-li-0035">IFN</term><def id="rmv2163-li-0036"><p>interferon</p></def></def-item><def-item><term id="rmv2163-li-0037">IRF3</term><def id="rmv2163-li-0038"><p>Interferon Regulatory Factor 3</p></def></def-item><def-item><term id="rmv2163-li-0039">ISG</term><def id="rmv2163-li-0040"><p>interferon&#x02010;stimulated gene</p></def></def-item><def-item><term id="rmv2163-li-0041">IVM</term><def id="rmv2163-li-0042"><p>ivermectin</p></def></def-item><def-item><term id="rmv2163-li-0043">LMWH</term><def id="rmv2163-li-0044"><p>low molecular weight heparin</p></def></def-item><def-item><term id="rmv2163-li-0045">MAPK</term><def id="rmv2163-li-0046"><p>mitogen&#x02010;activated protein kinase</p></def></def-item><def-item><term id="rmv2163-li-0047">MCL1</term><def id="rmv2163-li-0048"><p>myeloid cell leukaemia sequence 1</p></def></def-item><def-item><term id="rmv2163-li-0049">MDA5</term><def id="rmv2163-li-0050"><p>melanoma differentiation&#x02010;associated protein 5</p></def></def-item><def-item><term id="rmv2163-li-0051">MxA</term><def id="rmv2163-li-0052"><p>myxoma virus resistance A</p></def></def-item><def-item><term id="rmv2163-li-0053">NALP3</term><def id="rmv2163-li-0054"><p>NACHT, LRR, and PYD domains&#x02010;containing protein 3</p></def></def-item><def-item><term id="rmv2163-li-0055">NCT</term><def id="rmv2163-li-0056"><p>National Clinical Trial</p></def></def-item><def-item><term id="rmv2163-li-0057">PBEC</term><def id="rmv2163-li-0058"><p>primary bronchial epithelial cell</p></def></def-item><def-item><term id="rmv2163-li-0059">PGE2</term><def id="rmv2163-li-0060"><p>prostaglandin E2</p></def></def-item><def-item><term id="rmv2163-li-0061">PRR</term><def id="rmv2163-li-0062"><p>pattern recognition receptor</p></def></def-item><def-item><term id="rmv2163-li-0063">RIG&#x02010;1</term><def id="rmv2163-li-0064"><p>retinoic acid&#x02010;inducible gene 1</p></def></def-item><def-item><term id="rmv2163-li-0065">RV</term><def id="rmv2163-li-0066"><p>rhinovirus</p></def></def-item><def-item><term id="rmv2163-li-0067">SARS</term><def id="rmv2163-li-0068"><p>severe acute respiratory syndrome</p></def></def-item><def-item><term id="rmv2163-li-0069">TBK1</term><def id="rmv2163-li-0070"><p>TANK&#x02010;binding kinase 1</p></def></def-item><def-item><term id="rmv2163-li-0071">TGF&#x02010;beta</term><def id="rmv2163-li-0072"><p>transforming growth factor beta</p></def></def-item><def-item><term id="rmv2163-li-0073">TLR</term><def id="rmv2163-li-0074"><p>Toll&#x02010;like receptor</p></def></def-item></def-list><sec id="rmv2163-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Azithromycin (AZM) is a second&#x02010;generation, broad&#x02010;spectrum, synthetic macrolide antibiotic used since the early 1980s<xref rid="rmv2163-bib-0001" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="rmv2163-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> to treat a wide range of bacterial and mycobacterial infections of respiratory and skin infections. It is therefore on the WHO list of essential medications,<xref rid="rmv2163-bib-0003" ref-type="ref">
<sup>3</sup>
</xref> and manufactured on a large scale globally. Its antibacterial activity derives from its ability to bind to the 50S ribosomal subunit, inhibiting protein synthesis.<xref rid="rmv2163-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> It also has an intriguing range of anti&#x02010;viral and anti&#x02010;inflammatory properties, and is now being investigated as a potential candidate treatment for viruses including SARS&#x02010;CoV&#x02010;2, which causes coronavirus&#x02010;19 disease (COVID&#x02010;19). It has been used as a treatment in previous coronavirus diseases during the epidemics of severe acute respiratory syndrome (SARS) in 2003 and Middle East respiratory syndrome (MERS)<xref rid="rmv2163-bib-0005" ref-type="ref">
<sup>5</sup>
</xref> in 2012, but to date there are no randomised trial data on its use in any novel coronavirus infection. Its proven safety, affordability and global availability make it an attractive candidate for repurposing as a treatment for COVID&#x02010;19. Given the expected massive global impact of COVID&#x02010;19, particularly in low&#x02010;to&#x02010;middle income countries, it is important not only to develop therapies that treat the virus successfully, but also to ensure that these therapies are readily implementable at all levels of development and economy.<xref rid="rmv2163-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> This review summarizes the current understanding of the anti&#x02010;viral and anti&#x02010;inflammatory effects of AZM, with a view to supporting our knowledge in the pursuit of a COVID&#x02010;19 therapy that can help tackle this virus globally.</p></sec><sec id="rmv2163-sec-0002"><label>2</label><title>MECHANISMS OF ANTI&#x02010;VIRAL EFFECTS</title><p>A range of human in vitro and in vivo studies provide evidence of anti&#x02010;viral activity of macrolides across a broad range of viral species and families (Table <xref rid="rmv2163-tbl-0001" ref-type="table">1</xref>). Some studies suggest improved symptom resolution and reduction,<xref rid="rmv2163-bib-0017" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="rmv2163-bib-0018" ref-type="ref">
<sup>18</sup>
</xref>, <xref rid="rmv2163-bib-0019" ref-type="ref">
<sup>19</sup>
</xref>, <xref rid="rmv2163-bib-0020" ref-type="ref">
<sup>20</sup>
</xref>, <xref rid="rmv2163-bib-0021" ref-type="ref">
<sup>21</sup>
</xref>, <xref rid="rmv2163-bib-0022" ref-type="ref">
<sup>22</sup>
</xref> although not all studies have observed these effects.<xref rid="rmv2163-bib-0023" ref-type="ref">
<sup>23</sup>
</xref>, <xref rid="rmv2163-bib-0024" ref-type="ref">
<sup>24</sup>
</xref>, <xref rid="rmv2163-bib-0025" ref-type="ref">
<sup>25</sup>
</xref>, <xref rid="rmv2163-bib-0026" ref-type="ref">
<sup>26</sup>
</xref>
</p><table-wrap id="rmv2163-tbl-0001" xml:lang="en" content-type="TABLE" orientation="portrait" position="float"><label>TABLE 1</label><caption><p>Viral infections in which azithromycin has demonstrated anti&#x02010;viral effects</p></caption><table frame="hsides" rules="all"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Pathogen</th><th align="left" valign="bottom" rowspan="1" colspan="1">Findings</th><th align="left" valign="bottom" rowspan="1" colspan="1">Method</th><th align="left" valign="bottom" rowspan="1" colspan="1">Study</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Human rhinovirus (Picornavirus)</td><td align="left" valign="top" rowspan="1" colspan="1">Enhanced viral&#x02010;induced type I and III IFN leading to reduced RV replication and release</td><td align="left" valign="top" rowspan="1" colspan="1">In vitro study. PBEC. 10 &#x003bc;M, 50 &#x003bc;M</td><td align="left" valign="top" rowspan="1" colspan="1">Gielen et al<xref rid="rmv2163-bib-0007" ref-type="ref">
<sup>7</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Reduced RV replication</td><td align="left" valign="top" rowspan="1" colspan="1">In vitro study. PBEC from cystic fibrosis patients. 50 &#x003bc;M</td><td align="left" valign="top" rowspan="1" colspan="1">Schogler et al<xref rid="rmv2163-bib-0008" ref-type="ref">
<sup>8</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">In vitro study. PBECs and BEAS&#x02010;2B cells 50 &#x003bc;M, 10 &#x003bc;M</td><td align="left" valign="top" rowspan="1" colspan="1">Porter et al<xref rid="rmv2163-bib-0009" ref-type="ref">
<sup>9</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Increases RV PRR presentation</td><td align="left" valign="top" rowspan="1" colspan="1">In vitro study. PBEC. 10 &#x003bc;M, 50 &#x003bc;M</td><td align="left" valign="top" rowspan="1" colspan="1">Gielen et al<xref rid="rmv2163-bib-0007" ref-type="ref">
<sup>7</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Induces anti&#x02010;viral ISGs viperin and MxA</td><td align="left" valign="top" rowspan="1" colspan="1">In vitro study. PBECs and BEAS&#x02010;2B cells 50 &#x003bc;M, 10 &#x003bc;M</td><td align="left" valign="top" rowspan="1" colspan="1">Porter et al<xref rid="rmv2163-bib-0009" ref-type="ref">
<sup>9</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Coronaviruses (alpha and beta)</td><td align="left" valign="top" rowspan="1" colspan="1">AZM associated with reduced viral load in children with coronaviruses</td><td align="left" valign="top" rowspan="1" colspan="1">Clinical trial. Dose &#x02265;20 mg/kg</td><td align="left" valign="top" rowspan="1" colspan="1">Doan et al<xref rid="rmv2163-bib-0010" ref-type="ref">
<sup>10</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Zika (Flavivirus)</td><td align="left" valign="top" rowspan="1" colspan="1">AZM markedly reduces viral proliferation and virus&#x02010;induced cytopathic effects</td><td align="left" valign="top" rowspan="1" colspan="1">In vitro study. U87 glial cells and hPSC&#x02010;derived astrocytes, 0 &#x003bc;M to &#x0003e;100 &#x003bc;M</td><td align="left" valign="top" rowspan="1" colspan="1">Retallack et al<xref rid="rmv2163-bib-0011" ref-type="ref">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">AZM upregulates type I and III interferon responses</td><td align="left" valign="top" rowspan="1" colspan="1">In vitro study. HT&#x02010;29 human colon epithelial cell line and A549 lung epithelial cell line. 10 &#x003bc;M, 50 &#x003bc;M</td><td align="left" valign="top" rowspan="1" colspan="1">Li et al<xref rid="rmv2163-bib-0012" ref-type="ref">
<sup>12</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">AZM upregulates viral pathogen recognition receptors MDA5 and RIG&#x02010;1</td><td align="left" valign="top" rowspan="1" colspan="1">In vitro study. A549 lung epithelial cell line. 10 &#x003bc;M, 50 &#x003bc;M</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">AZM increases levels of phosphorylated TBK1 and IRF3</td><td align="left" valign="top" rowspan="1" colspan="1">In vitro study. HT&#x02010;29 human colon epithelial cell line, 10 &#x003bc;M, 50 &#x003bc;M</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Human primary fibroblasts, 5 &#x003bc;M, 20 &#x003bc;M. RAW264.7 macrophage cells 1.5 &#x003bc;M, 3 &#x003bc;M</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Enteroviruses (Picornaviruses)</td><td align="left" valign="top" rowspan="1" colspan="1">AZM improved survival and clinical symptom scores in murine model</td><td align="left" valign="top" rowspan="1" colspan="1">In vivo study. Mice infected i.p. with EV&#x02010;A71&#x02010;MZ&#x02010;MA1. AZM dose 30&#x02009;mg/kg/day</td><td align="left" valign="top" rowspan="1" colspan="1">Zeng et al<xref rid="rmv2163-bib-0013" ref-type="ref">
<sup>13</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ebola (Ebola viruses)</td><td align="left" valign="top" rowspan="1" colspan="1">AZM demonstrates high in vitro anti&#x02010;viral potency and low cytotoxicity</td><td align="left" valign="top" rowspan="1" colspan="1">In vitro study. HeLa cells (viral replication). HEK 293T cells (viral entry and cytotoxicity). 0.5 to 50 &#x003bc;M</td><td align="left" valign="top" rowspan="1" colspan="1">Madrid et al<xref rid="rmv2163-bib-0014" ref-type="ref">
<sup>14</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SARS (Coronavirus)</td><td align="left" valign="top" rowspan="1" colspan="1">AZM associated with improvement in 90 d survival rate and time to discontinuation of mechanical ventilation</td><td align="left" valign="top" rowspan="1" colspan="1">Single&#x02010;centre, retrospective cohort evaluation of hospitalized patients with moderate or severe ARDS, using a propensity score analysis</td><td align="left" valign="top" rowspan="1" colspan="1">Kawamura et al<xref rid="rmv2163-bib-0015" ref-type="ref">
<sup>15</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Influenza A (Orthomyxovirus)</td><td align="left" valign="top" rowspan="1" colspan="1">Reduction in IL&#x02010;6, IL&#x02010;8, IL&#x02010;17, CXCL9, sTNF and CRP</td><td align="left" valign="top" rowspan="1" colspan="1">Randomised, open&#x02010;label, multicentre trial of patients with severe influenza. 500 mg AZM od + 75 mg oseltamivir bd/75&#x02009;mg oseltamivir bd.</td><td align="left" valign="top" rowspan="1" colspan="1">Lee et al<xref rid="rmv2163-bib-0016" ref-type="ref">
<sup>16</sup>
</xref>
</td></tr></tbody></table><table-wrap-foot id="rmv2163-ntgp-0001"><fn id="rmv2163-note-0001"><p>Abbreviations: AZM, azithromycin; CRP, C&#x02010;reactive protein; CXCL, C&#x02010;X&#x02010;C motif ligand; hPSC, human pluripotent stem cell; IL, interleukin; IFN, interferon; IRF3, Interferon Regulatory Factor 3; ISG, interferon&#x02010;stimulated gene; MDA5, melanoma differentiation&#x02010;associated protein 5; MxA, myxoma virus resistance A; PBEC, primary bronchial epithelial cell; PRR, pattern recognition receptor; RIG&#x02010;1, retinoic acid&#x02010;inducible gene 1, RV, rhinovirus; SARS, severe acute respiratory syndrome; TBK1, TANK&#x02010;binding kinase 1.</p></fn></table-wrap-foot></table-wrap><sec id="rmv2163-sec-0003"><label>2.1</label><title>Mechanisms of anti&#x02010;viral effects against rhinovirus</title><p>In several clinical trials, macrolides reduced exacerbations in airways diseases, particularly asthma.<xref rid="rmv2163-bib-0027" ref-type="ref">
<sup>27</sup>
</xref>, <xref rid="rmv2163-bib-0028" ref-type="ref">
<sup>28</sup>
</xref>, <xref rid="rmv2163-bib-0029" ref-type="ref">
<sup>29</sup>
</xref>, <xref rid="rmv2163-bib-0030" ref-type="ref">
<sup>30</sup>
</xref> As the majority of such exacerbations are triggered by viral infections,<xref rid="rmv2163-bib-0031" ref-type="ref">
<sup>31</sup>
</xref> most commonly rhinoviruses (RV),<xref rid="rmv2163-bib-0032" ref-type="ref">
<sup>32</sup>
</xref> the effects of macrolides have been studied most extensively against RV. AZM reduces RV replication and release during in vitro infection of primary human bronchial epithelial cells (PBEC).<xref rid="rmv2163-bib-0007" ref-type="ref">
<sup>7</sup>
</xref> This finding was replicated in PBEC from patients with cystic fibrosis or healthy controls, where AZM treatment again led to a sevenfold to ninefold reduction in viral shedding, respectively.<xref rid="rmv2163-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> The use of AZM alone increased viral&#x02010;induced interferons (IFNs) and interferon&#x02010;stimulated gene (ISG) mRNA expression and hence production of these gene products.<xref rid="rmv2163-bib-0007" ref-type="ref">
<sup>7</sup>
</xref>, <xref rid="rmv2163-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> In the latter study, while viral replication was suppressed, AZM did not suppress pro&#x02010;inflammatory responses.</p><p>In vivo data from the AMAZES study, the largest clinical trial of a long&#x02010;term macrolide in airways disease, showed a striking 40% reduction in asthma exacerbations with AZM.<xref rid="rmv2163-bib-0029" ref-type="ref">
<sup>29</sup>
</xref> The mechanism is unknown, and would be consistent with an anti&#x02010;viral effect, although metagenomic analyses suggest an antibacterial effect reducing <italic>Haemophilus influenzae</italic>
<xref rid="rmv2163-bib-0033" ref-type="ref">
<sup>33</sup>
</xref>, <xref rid="rmv2163-bib-0034" ref-type="ref">
<sup>34</sup>
</xref> may be the predominant mechanism. The effect on viruses may relate to <italic>H. influenzae</italic> upregulation of ICAM&#x02010;1, a major receptor for both <italic>Haemophilus</italic> and rhinovirus (RV).<xref rid="rmv2163-bib-0035" ref-type="ref">
<sup>35</sup>
</xref>
</p><p>Other macrolides also have anti&#x02010;viral effects in RV infection including Mac5, an oleandomycin macrolide. Both AZM and Mac5 suppressed RV replication and enhanced RV&#x02010;induced type I and type III IFNs, as well as the ISGs viperin/MxA.<xref rid="rmv2163-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> In this study, macrolides did not affect interleukin (IL)&#x02010;6 and &#x02010;8, but secretion of IL&#x02010;1&#x003b2;, IL&#x02010;6 and IL&#x02010;8 were reduced by clarithromycin (another macrolide) in a separate study of RV,<xref rid="rmv2163-bib-0036" ref-type="ref">
<sup>36</sup>
</xref> alongside inhibition of viral replication and ICAM&#x02010;1. Macrolides such as AZM augment infection&#x02010;induced IFN responses.<xref rid="rmv2163-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> This is of relevance to coronaviruses as type I IFN inhibit replication of both SARS&#x02010;CoV<xref rid="rmv2163-bib-0037" ref-type="ref">
<sup>37</sup>
</xref> and SARS&#x02010;CoV&#x02010;2<xref rid="rmv2163-bib-0038" ref-type="ref">
<sup>38</sup>
</xref> in vitro.</p><p>RV replication was also inhibited by the macrolides erythromycin<xref rid="rmv2163-bib-0039" ref-type="ref">
<sup>39</sup>
</xref> and bafilomycin<xref rid="rmv2163-bib-0040" ref-type="ref">
<sup>40</sup>
</xref> in PBEC. In both studies, macrolides reduced RV&#x02010;induced NF&#x003ba;B activation and decreased acidity of endosomes in epithelial cells. Bafilomycin inhibited cytokine production and ICAM&#x02010;1 expression.</p></sec><sec id="rmv2163-sec-0004"><label>2.2</label><title>Mechanism of effects in influenza A</title><p>In a randomised trial in patients with influenza A receiving oseltamivir, 5&#x02009;days' adjunctive AZM 500&#x02009;mg daily was associated with more rapid reductions in plasma concentrations of IL&#x02010;6, IL&#x02010;8, IL&#x02010;17, CXCL9, soluble tissue necrosis factor (TNF) and C&#x02010;reactive protein (CRP).<xref rid="rmv2163-bib-0016" ref-type="ref">
<sup>16</sup>
</xref> However, this was an open&#x02010;label study, with a small sample size (n = 50), and the effect was small, with no significant changes in viral clearance or time to symptom resolution. In a second, larger, open&#x02010;label, randomised controlled trial 2&#x02009;days of clarithromycin 500&#x02009;mg and naproxen 200&#x02009;mg twice daily reduced 30&#x02009;day mortality, high dependency unit admission and hospital stay in 217 elderly patients with H2N2 influenza.<xref rid="rmv2163-bib-0018" ref-type="ref">
<sup>18</sup>
</xref> The effect size was marked, although the study is limited by lack of blinding and by the likelihood that much of the effect might be attributable to the antibacterial properties of clarithromycin, as bacterial pneumonias are responsible for a high proportion of influenza deaths, particularly in the elderly.</p><p>Nonetheless in vitro clarithromycin reduced viral replication in the A549 human lung cell line.<xref rid="rmv2163-bib-0041" ref-type="ref">
<sup>41</sup>
</xref> Likewise clarithromycin reduced viral titres and supernatant cytokines on cultured human tracheal epithelial cells, associated with reduction in surface expression of the influenza A receptor S&#x003b1;2, 6Gal, inhibition of NF&#x003ba;B and reduced acidification of the endosome required for intracellular release of viral RNA.<xref rid="rmv2163-bib-0042" ref-type="ref">
<sup>42</sup>
</xref> More recent data also showed a reduction in H1N1 viral replication in A549 cells with AZM with an IC<sub>50</sub> of 68 &#x003bc;M, with an effect most apparent during viral particle internalisation.<xref rid="rmv2163-bib-0043" ref-type="ref">
<sup>43</sup>
</xref>
</p><p>Some murine studies have investigated macrolides in vivo. Erythromycin improved survival during severe H2N2 infection,<xref rid="rmv2163-bib-0044" ref-type="ref">
<sup>44</sup>
</xref> associated with reduced bronchoalveolar lavage (BAL) IFN&#x02010;&#x003b3;, inflammatory cells and nitric&#x02010;oxide&#x02010;derived free radicals. Other macrolides leucomycin A3, spiramycin and a non&#x02010;antibacterial erythromycin derivative (EM900) each reduced weight loss, improved survival and reduced viral protein expression in H1N1 influenza.<xref rid="rmv2163-bib-0045" ref-type="ref">
<sup>45</sup>
</xref> In a short&#x02010;term H1N1 infection model, AZM reduced expression of viral proteins 2&#x02009;days post infection.<xref rid="rmv2163-bib-0043" ref-type="ref">
<sup>43</sup>
</xref> However, the effect was not sustained, and not associated with a change in virus&#x02010;induced weight loss, a sensitive measurement of influenza pathology. Another study found AZM reduced lung viral titres at day 6 post infection, though the effects were not additive to that achieved with oseltamivir in terms of survival, viral titres or cytokine levels,<xref rid="rmv2163-bib-0046" ref-type="ref">
<sup>46</sup>
</xref> and so these data remain conflicting.<xref rid="rmv2163-bib-0047" ref-type="ref">
<sup>47</sup>
</xref> In a separate influenza study, AZM decreased total leukocyte accumulation in lung tissue and BAL, with the largest reduction being in neutrophils, and associated with decreased inflammatory mediators.</p></sec><sec id="rmv2163-sec-0005"><label>2.3</label><title>Mechanism of anti&#x02010;viral effect in Zika virus</title><p>In a drug screen of 2177 compounds against the flavivirus Zika, AZM reduced viral proliferation and virus&#x02010;induced cytopathic effects in glial cell lines and human astrocytes.<xref rid="rmv2163-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> A further in vitro study found AZM to effectively suppress Zika infection by targeting a late stage in the viral life cycle.<xref rid="rmv2163-bib-0012" ref-type="ref">
<sup>12</sup>
</xref> AZM also upregulated expression of type I and III IFNs and several of their downstream ISGs, paralleling activities of AZM in RV.<xref rid="rmv2163-bib-0007" ref-type="ref">
<sup>7</sup>
</xref>, <xref rid="rmv2163-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> Furthermore, AZM induced enhanced expression of the anti&#x02010;viral pattern recognition receptors (PRRs) MDA5 and RIG&#x02010;1, as well as the levels of phosphorylated TBK1 and IRF3.</p></sec><sec id="rmv2163-sec-0006"><label>2.4</label><title>Anti&#x02010;viral effects in Ebola</title><p>AZM was similarly evaluated in a drug screen for its efficacy as a therapy for Ebola.<xref rid="rmv2163-bib-0014" ref-type="ref">
<sup>14</sup>
</xref> While AZM demonstrated high in vitro potency (50% effective concentration [EC<sub>50</sub>] = 5.1 &#x003bc;M) and low toxicity, when tested in an in vivo mouse model it did not consistently improve survival in mice or guinea pigs.</p></sec><sec id="rmv2163-sec-0007"><label>2.5</label><title>Anti&#x02010;viral effects in enteroviruses</title><p>Enterovirus A71 (EV&#x02010;A71) causes hand, foot and mouth disease in young children. AZM and spiramycin (another macrolide) provided significant in vivo protection against EV&#x02010;A71 infection in mice.<xref rid="rmv2163-bib-0013" ref-type="ref">
<sup>13</sup>
</xref> Spiramycin impaired EV&#x02010;A71 viral RNA synthesis, and it is likely spiramycin and AZM work through a common mechanism, after viral entry, impairing viral RNA synthesis either directly or indirectly.</p></sec><sec id="rmv2163-sec-0008"><label>2.6</label><title>Anti&#x02010;viral effects of <styled-content style="fixed-case" toggle="no">AZM</styled-content> in coronaviruses</title><p>Human coronaviruses are enveloped positive&#x02010;stranded RNA viruses of the <italic>Coronaviridae</italic> family in the <italic>Nidovirales</italic> order comprising four genera (<italic>Alpha&#x02010;</italic>, <italic>Beta&#x02010;</italic>, <italic>Gamma</italic>&#x02010;, <italic>Delta</italic>&#x02010;<italic>coronaviruses</italic>).<xref rid="rmv2163-bib-0048" ref-type="ref">
<sup>48</sup>
</xref> These viruses are endemic respiratory and gastrointestinal viruses and the <italic>Betacoronavirus</italic> genus includes the pandemic viruses MERS&#x02010;CoV, SARS&#x02010;CoV and SARS&#x02010;CoV&#x02010;2. AZM was used in a third of patients treated for MERS&#x02010;CoV, although without a clinical evidence base.<xref rid="rmv2163-bib-0005" ref-type="ref">
<sup>5</sup>
</xref> A retrospective cohort analysis of 349 patients across 14 sites in Saudi Arabia found no significant reduction in 90&#x02010;day mortality (odds ratio [OR] 0.84 95% confidence interval [CI] 0.47&#x02010;1.51) or improvement in MERS&#x02010;CoV RNA clearance (hazard ratio HR 0.88 [0.47&#x02010;1.64] with macrolide use).<xref rid="rmv2163-bib-0005" ref-type="ref">
<sup>5</sup>
</xref> However, this was a non&#x02010;randomised, retrospective observational study, in which it was unknown on what basis treatment allocation decisions were made, and randomised data are needed.</p><p>Interesting data have recently emerged from a mass eradication programme amongst preschool children in Niger. Children up to age 5 were cluster&#x02010;randomised by community to a single oral dose of AZM or placebo every 6 months and nasopharyngeal swabs were taken for viral RNA sequencing. After 24&#x02009;months, AZM use was associated with an eightfold reduction in viral load of <italic>Alphacoronavirus</italic> and a 14&#x02010;fold reduction in <italic>Betacoronavirus</italic> viral load, though there was no difference in the prevalence of these viruses.<xref rid="rmv2163-bib-0010" ref-type="ref">
<sup>10</sup>
</xref>
</p><p>Since the outbreak of the current SARS&#x02010;CoV&#x02010;2 pandemic, several drug screens have investigated potential candidate drugs against this virus. A screen of 1520 approved and off&#x02010;patent drugs identified 90 drugs which inhibited SARS&#x02010;CoV&#x02010;2 viral replication at 10 &#x003bc;M.<xref rid="rmv2163-bib-0048" ref-type="ref">
<sup>48</sup>
</xref> These included ATPase proton pump inhibitors, protease inhibitors, viral protease inhibitors, drugs targeting the angiotensin pathway and AZM. AZM had an EC<sub>50</sub> of 2.12 &#x003bc;M and EC<sub>90</sub> 8.65, and selectivity index &#x0003e;19, which is very comparable to the control compound remdesivir (EC<sub>50</sub> =&#x02009;1.65, EC<sub>90</sub> =&#x02009;2.52), the only anti&#x02010;viral with proven clinical efficacy against SARS&#x02010;CoV&#x02010;2 in clinical trials to date.<xref rid="rmv2163-bib-0049" ref-type="ref">
<sup>49</sup>
</xref>, <xref rid="rmv2163-bib-0050" ref-type="ref">
<sup>50</sup>
</xref> Likewise AZM was also identified as a target in a bioinformatic screening analysis of potentially relevant pathways with the potential for development into pharmaceutically acceptable forms,<xref rid="rmv2163-bib-0051" ref-type="ref">
<sup>51</sup>
</xref> in this case by inhibiting autophagy via inhibition of the vacuolar ATPase necessary for autophagosome&#x02010;lysosome fusion.<xref rid="rmv2163-bib-0052" ref-type="ref">
<sup>52</sup>
</xref> A focussed study on two candidate molecules, hydroxychloroquine and AZM, suggested a synergistic inhibition of SARS&#x02010;CoV&#x02010;2 replication in Vero cells at 5 and 10 &#x003bc;M concentrations, respectively.<xref rid="rmv2163-bib-0053" ref-type="ref">
<sup>53</sup>
</xref> This synergy has been proposed to allow effective use of hydroxychloroquine at less toxic concentrations, and is an approach tried in a small observational study which suggested enhanced virological clearance with hydroxychloroquine, particularly in combination with AZM.<xref rid="rmv2163-bib-0054" ref-type="ref">
<sup>54</sup>
</xref> However this study was very small, with AZM data from only six patients, and was open&#x02010;label and non&#x02010;randomised, allowing no useful conclusions to be drawn. Moreover, there are concerns that combination therapy may enhance cardiovascular side effects as both molecules individually can cause prolongation of the QT interval.<xref rid="rmv2163-bib-0055" ref-type="ref">
<sup>55</sup>
</xref> This combination has been tested in non&#x02010;human primates, where a significant anti&#x02010;viral effect was not seen in the five macaques which received AZM in addition to hydroxychloroquine.<xref rid="rmv2163-bib-0056" ref-type="ref">
<sup>56</sup>
</xref>
</p></sec></sec><sec id="rmv2163-sec-0009"><label>3</label><title>ANTI&#x02010;INFLAMMATORY EFFECTS</title><p>Whilst viruses can cause tissue damage by direct cytopathic effects on the infected cells, morbidity and mortality in severe disease are typically attributable to the host inflammatory response, including in COVID&#x02010;19.<xref rid="rmv2163-bib-0057" ref-type="ref">
<sup>57</sup>
</xref> AZM and other macrolides have a number of immunomodulatory properties which have proven clinical efficacy in a broad range of respiratory diseases including asthma,<xref rid="rmv2163-bib-0029" ref-type="ref">
<sup>29</sup>
</xref> COPD,<xref rid="rmv2163-bib-0058" ref-type="ref">
<sup>58</sup>
</xref> post lung transplant obliterative bronchiolitis<xref rid="rmv2163-bib-0059" ref-type="ref">
<sup>59</sup>
</xref> and diffuse pan bronchiolitis (DPB).<xref rid="rmv2163-bib-0060" ref-type="ref">
<sup>60</sup>
</xref>, <xref rid="rmv2163-bib-0061" ref-type="ref">
<sup>61</sup>
</xref>, <xref rid="rmv2163-bib-0062" ref-type="ref">
<sup>62</sup>
</xref>, <xref rid="rmv2163-bib-0063" ref-type="ref">
<sup>63</sup>
</xref> In DPB, a dramatic increase in survival<xref rid="rmv2163-bib-0060" ref-type="ref">
<sup>60</sup>
</xref>, <xref rid="rmv2163-bib-0062" ref-type="ref">
<sup>62</sup>
</xref>, <xref rid="rmv2163-bib-0063" ref-type="ref">
<sup>63</sup>
</xref> has been attributed to the ability of AZM to inhibit dysregulated IL&#x02010;1&#x003b2;, IL&#x02010;2, TNF and GM&#x02010;CSF.<xref rid="rmv2163-bib-0064" ref-type="ref">
<sup>64</sup>
</xref> Therefore, the anti&#x02010;inflammatory properties of AZM (summarised in Table <xref rid="rmv2163-tbl-0002" ref-type="table">2</xref> and Figure <xref rid="rmv2163-fig-0001" ref-type="fig">1</xref>) may be clinically important in the management of viral diseases.</p><table-wrap id="rmv2163-tbl-0002" xml:lang="en" content-type="TABLE" orientation="portrait" position="float"><label>TABLE 2</label><caption><p>Immunomodulatory and anti&#x02010;inflammatory properties of azithromycin</p></caption><table frame="hsides" rules="all"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Property</th><th align="left" valign="bottom" rowspan="1" colspan="1">Effect</th><th align="left" valign="bottom" rowspan="1" colspan="1">Specific Findings</th><th align="left" valign="bottom" rowspan="1" colspan="1">Study</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">General anti&#x02010;inflammatory properties</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Destabilisation of NALP3 mRNA levels</td><td align="left" valign="top" rowspan="1" colspan="1">Decreased IL&#x02010;beta production</td><td align="left" valign="top" rowspan="1" colspan="1">LPS&#x02010;stimulated THP&#x02010;1 monocytes. AZM reduced IL&#x02010;1beta, NALP3 protein and NF&#x003ba;B activity</td><td align="left" valign="top" rowspan="1" colspan="1">Lendermon et al<xref rid="rmv2163-bib-0065" ref-type="ref">
<sup>65</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Inhibition of inflammatory cytokine release</td><td align="left" valign="top" rowspan="1" colspan="1">Decreased CXCL8 (IL&#x02010;8), NF&#x003ba;B and AP&#x02010;1 from epithelial cells</td><td align="left" valign="top" rowspan="1" colspan="1">Clinical trial in recurrent genital <italic>C. trachomatis</italic> infection. Decreased IL&#x02010;1beta, CXCL&#x02010;1, &#x02010;5, &#x02010;8, &#x02010;9, CCL2, &#x02010;5, MCL1, MAPK1</td><td align="left" valign="top" rowspan="1" colspan="1">Srivastava et al<xref rid="rmv2163-bib-0066" ref-type="ref">
<sup>66</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Airway epithelial cell lines. Decrease in CXCL8 mRNA, and NF&#x003ba;B and AP&#x02010;1 binding</td><td align="left" valign="top" rowspan="1" colspan="1">Cigana et al<xref rid="rmv2163-bib-0067" ref-type="ref">
<sup>67</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Decreased CXCL8 (IL&#x02010;8), MAPK and 8&#x02010;isoprostane in airway smooth muscle cells</td><td align="left" valign="top" rowspan="1" colspan="1">IL&#x02010;17&#x02010;stimulated primary human airway smooth muscle cells</td><td align="left" valign="top" rowspan="1" colspan="1">Vanaudenaerde et al<xref rid="rmv2163-bib-0068" ref-type="ref">
<sup>68</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Decreased PGE2 synthesis</td><td align="left" valign="top" rowspan="1" colspan="1">Human polymorphonuclear and mononuclear leukocytes. Decreased LPS&#x02010;induced PGE2 by suppression of cPLA2, COX&#x02010;1, COX&#x02010;2</td><td align="left" valign="top" rowspan="1" colspan="1">Miyazaki et al<xref rid="rmv2163-bib-0069" ref-type="ref">
<sup>69</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Decreased TNF from cystic fibrosis airway epithelial cells</td><td align="left" valign="top" rowspan="1" colspan="1">Human CF and non&#x02010;CF cell lines. Decreased TNF mRNA and protein and NF&#x003ba;B and Sp1 binding</td><td align="left" valign="top" rowspan="1" colspan="1">Cigana et al<xref rid="rmv2163-bib-0070" ref-type="ref">
<sup>70</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Decreased GM&#x02010;CSF</td><td align="left" valign="top" rowspan="1" colspan="1">Airway epithelial (A549) cell lines. Reduced TNF&#x02010;induced GM&#x02010;CSF mRNA and protein expression</td><td align="left" valign="top" rowspan="1" colspan="1">Yamasawa et al<xref rid="rmv2163-bib-0071" ref-type="ref">
<sup>71</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Reduction of cytokine&#x02010;induced endothelin 1 expression in epithelial cells</td><td align="left" valign="top" rowspan="1" colspan="1">Human bronchial epithelial cells. Erythromycin and clarithromycin reduced enfothelin&#x02010;1 expression</td><td align="left" valign="top" rowspan="1" colspan="1">Takizawa et al<xref rid="rmv2163-bib-0072" ref-type="ref">
<sup>72</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Inhibition of endocytosis/induction of phospholipidosis</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Decreases motility and fluidity of the plasma membrane</td><td align="left" valign="top" rowspan="1" colspan="1">J774 macrophage cell line</td><td align="left" valign="top" rowspan="1" colspan="1">Tyteca et al<xref rid="rmv2163-bib-0073" ref-type="ref">
<sup>73</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Slows membrane trafficking towards lysosomes</td><td align="left" valign="top" rowspan="1" colspan="1">J774 macrophage cell line</td><td align="left" valign="top" rowspan="1" colspan="1">Tyteca et al<xref rid="rmv2163-bib-0074" ref-type="ref">
<sup>74</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Inhibition of fluid phase endocytosis of macromolecules</td><td align="left" valign="top" rowspan="1" colspan="1">J774 macrophage cell line</td><td align="left" valign="top" rowspan="1" colspan="1">Tyteca et al<xref rid="rmv2163-bib-0074" ref-type="ref">
<sup>74</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Down&#x02010;regulates and delays recycling of surface transferrin receptors</td><td align="left" valign="top" rowspan="1" colspan="1">J774 macrophage cell line</td><td align="left" valign="top" rowspan="1" colspan="1">Tyteca et al<xref rid="rmv2163-bib-0074" ref-type="ref">
<sup>74</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Inhibition of pinocytosis of macromolecules and their transport from plasma membrane to endo/lysosomes</td><td align="left" valign="top" rowspan="1" colspan="1">J774 macrophage cell line</td><td align="left" valign="top" rowspan="1" colspan="1">Tyteca et al<xref rid="rmv2163-bib-0074" ref-type="ref">
<sup>74</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Increase of lysosomal hydrolase activity in fibroblasts</td><td align="left" valign="top" rowspan="1" colspan="1">Fibroblast homogenates. Increased activity of sulfatase A, phospholipase A1, cathepsin B</td><td align="left" valign="top" rowspan="1" colspan="1">Gerbaux et al<xref rid="rmv2163-bib-0075" ref-type="ref">
<sup>75</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Lysosomal enzyme depletion/extracellular secretion of lysosomal enzymes</td><td align="left" valign="top" rowspan="1" colspan="1">Rat kidney cells. Redistribution of mannose 6&#x02010;phosphate receptor</td><td align="left" valign="top" rowspan="1" colspan="1">Ikeda et al<xref rid="rmv2163-bib-0076" ref-type="ref">
<sup>76</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Effects on airway inflammatory cells</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Accumulation intracellularly within phagocytes</td><td align="left" valign="top" rowspan="1" colspan="1">Prolonged macrolide retention intracellularly</td><td align="left" valign="top" rowspan="1" colspan="1">Human in vivo 210 h T1/2 in neutrophils. Concentration in alveolar macrophages, in neutrophils, in phagocytic and epithelial cell lines</td><td align="left" valign="top" rowspan="1" colspan="1">Wildfeuer et al, Capitano et al, Bosnar et al<xref rid="rmv2163-bib-0077" ref-type="ref">
<sup>77</sup>
</xref>, <xref rid="rmv2163-bib-0078" ref-type="ref">
<sup>78</sup>
</xref>, <xref rid="rmv2163-bib-0079" ref-type="ref">
<sup>79</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Prolonged AZM retention within neutrophils</td><td align="left" valign="top" rowspan="1" colspan="1">Concentrations 2000 to 3000 times higher in neutrophils than plasma</td><td align="left" valign="top" rowspan="1" colspan="1">Wilms et al<xref rid="rmv2163-bib-0080" ref-type="ref">
<sup>80</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Accumulation of macrolides in alveolar macrophages</td><td align="left" valign="top" rowspan="1" colspan="1">Human in vivo 500&#x02010;fold accumulation in alveolar macrophages</td><td align="left" valign="top" rowspan="1" colspan="1">Lucchi et al, Capitano et al<xref rid="rmv2163-bib-0077" ref-type="ref">
<sup>77</sup>
</xref>, <xref rid="rmv2163-bib-0081" ref-type="ref">
<sup>81</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Neutrophils</td><td align="left" valign="top" rowspan="1" colspan="1">Inhibition of neutrophil chemotaxis</td><td align="left" valign="top" rowspan="1" colspan="1">Murine pseudomonas model and human neutrophils. Reduced neutrophil chemotaxis via ERK&#x02010;1 and ERK&#x02010;2</td><td align="left" valign="top" rowspan="1" colspan="1">Tsai et al<xref rid="rmv2163-bib-0082" ref-type="ref">
<sup>82</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Down regulation of neutrophil chemokine production</td><td align="left" valign="top" rowspan="1" colspan="1">Human blood. Decreased azurophilic granule enzyme activities</td><td align="left" valign="top" rowspan="1" colspan="1">Culi&#x00107; et al, Tsai et al<xref rid="rmv2163-bib-0083" ref-type="ref">
<sup>83</sup>
</xref>, <xref rid="rmv2163-bib-0084" ref-type="ref">
<sup>84</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Attenuation of neutrophil oxidative burst</td><td align="left" valign="top" rowspan="1" colspan="1">Human blood neutrophils</td><td align="left" valign="top" rowspan="1" colspan="1">Nozoe et al<xref rid="rmv2163-bib-0085" ref-type="ref">
<sup>85</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Down regulation of MPO production</td><td align="left" valign="top" rowspan="1" colspan="1">Human in vivo blood neutrophils. Decreased MPO concentration</td><td align="left" valign="top" rowspan="1" colspan="1">Culi&#x00107; et al<xref rid="rmv2163-bib-0084" ref-type="ref">
<sup>84</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Increased neutrophil apoptosis</td><td align="left" valign="top" rowspan="1" colspan="1">Human in vivo blood neutrophils. Increased neutrophil apoptosis 28&#x02009;days post dose</td><td align="left" valign="top" rowspan="1" colspan="1">Culi&#x00107; et al<xref rid="rmv2163-bib-0084" ref-type="ref">
<sup>84</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Inhibition of neutrophil elastase and MMP9</td><td align="left" valign="top" rowspan="1" colspan="1">Human in vivo. Clarithromycin reduced airway neutrophil elastase and MMP9</td><td align="left" valign="top" rowspan="1" colspan="1">Simpson et al<xref rid="rmv2163-bib-0086" ref-type="ref">
<sup>86</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Macrophages</td><td align="left" valign="top" rowspan="1" colspan="1">Increased phagocytosis</td><td align="left" valign="top" rowspan="1" colspan="1">Human alveolar macrophages. Increased phagocytosis of apoptotic bronchial epithelial cells and neutrophils</td><td align="left" valign="top" rowspan="1" colspan="1">Hodge et al, Yamaryo et al<xref rid="rmv2163-bib-0087" ref-type="ref">
<sup>87</sup>
</xref>, <xref rid="rmv2163-bib-0088" ref-type="ref">
<sup>88</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Macrophage lysosomes more resistant to oxidant challenge</td><td align="left" valign="top" rowspan="1" colspan="1">Human alveolar macrophages ex vivo. Reduced oxidative lysosomal membrane permeabilisation</td><td align="left" valign="top" rowspan="1" colspan="1">Persson et al<xref rid="rmv2163-bib-0089" ref-type="ref">
<sup>89</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Polarization towards M2 phenotype</td><td align="left" valign="top" rowspan="1" colspan="1">In vitro polarised J774 macrophage cell line. Increased M2 markers mannose receptor, CD23, arginase, decreased CCR7</td><td align="left" valign="top" rowspan="1" colspan="1">Murphy et al<xref rid="rmv2163-bib-0090" ref-type="ref">
<sup>90</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Reduction in production of GM&#x02010;CSF and IL&#x02010;1beta</td><td align="left" valign="top" rowspan="1" colspan="1">Murine LPS challenge. Decreased GM&#x02010;CSF, IL&#x02010;1beta, TNF, CCL2</td><td align="left" valign="top" rowspan="1" colspan="1">Bosnar et al<xref rid="rmv2163-bib-0091" ref-type="ref">
<sup>91</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Suppression of IL&#x02010;12p40 by macrophages</td><td align="left" valign="top" rowspan="1" colspan="1">LPS&#x02010;stimulated macrophage cell lines. Decreased IL&#x02010;12p40 induction by inhibited AP&#x02010;1, NFAT, ICSBP binding</td><td align="left" valign="top" rowspan="1" colspan="1">Yamauchi et al<xref rid="rmv2163-bib-0092" ref-type="ref">
<sup>92</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Increased mannose receptor expression</td><td align="left" valign="top" rowspan="1" colspan="1">Human in vivo trial. Increased mannose receptor expression and phagocytosis</td><td align="left" valign="top" rowspan="1" colspan="1">Hodge et al<xref rid="rmv2163-bib-0093" ref-type="ref">
<sup>93</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Decreased CXCL8 (IL&#x02010;8) production</td><td align="left" valign="top" rowspan="1" colspan="1">Human ex vivo blood and lung macrophages. CXCL8 inhibited at 400 mg/L</td><td align="left" valign="top" rowspan="1" colspan="1">Kurdowska et al<xref rid="rmv2163-bib-0094" ref-type="ref">
<sup>94</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Dendritic cells</td><td align="left" valign="top" rowspan="1" colspan="1">Modulation towards a regulatory phenotype</td><td align="left" valign="top" rowspan="1" colspan="1">Monocyte&#x02010;derived dendritic cells enhanced IL&#x02010;10 release and inhibited IL&#x02010;6, IL&#x02010;12p40, CXCL10, CXCL11 and CCL22 release</td><td align="left" valign="top" rowspan="1" colspan="1">Polancec et al, Sugiyama et al<xref rid="rmv2163-bib-0095" ref-type="ref">
<sup>95</sup>
</xref>, <xref rid="rmv2163-bib-0096" ref-type="ref">
<sup>96</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">CD40, CD86, and MHCII expression inhibited</td><td align="left" valign="top" rowspan="1" colspan="1">Murine bone marrow derived DCs and murine histoincompatible bone marrow transplant model. Decreased CD40 and CD86</td><td align="left" valign="top" rowspan="1" colspan="1">Iwamoto et al<xref rid="rmv2163-bib-0097" ref-type="ref">
<sup>97</sup>
</xref>, <xref rid="rmv2163-bib-0098" ref-type="ref">
<sup>98</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Natural Killer cells</td><td align="left" valign="top" rowspan="1" colspan="1">Inhibition of cytotoxic function through down regulation of perforin expression</td><td align="left" valign="top" rowspan="1" colspan="1">Human NK cells. Decreased CD69, perforin and cytotoxicity</td><td align="left" valign="top" rowspan="1" colspan="1">Lin et al<xref rid="rmv2163-bib-0099" ref-type="ref">
<sup>99</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Effects on airway mucosal stromal cells</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Smooth muscle cells</td><td align="left" valign="top" rowspan="1" colspan="1">Antiproliferative effect</td><td align="left" valign="top" rowspan="1" colspan="1">Rabbit tracheal smooth muscle cells. Reduced proliferation, increased autophagy</td><td align="left" valign="top" rowspan="1" colspan="1">Stamatiou et al<xref rid="rmv2163-bib-0100" ref-type="ref">
<sup>100</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Relaxant effect</td><td align="left" valign="top" rowspan="1" colspan="1">Rabbit tracheal smooth muscle cells. Smooth muscle relaxation</td><td align="left" valign="top" rowspan="1" colspan="1">Daenas et al<xref rid="rmv2163-bib-0101" ref-type="ref">
<sup>101</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Airway epithelium</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Enhanced airway epithelial integrity</td><td align="left" valign="top" rowspan="1" colspan="1">Increased transepithelial electrical resistance by altered processing of tight junction proteins</td><td align="left" valign="top" rowspan="1" colspan="1">Asgrimsson et al, Halldorsson et al<xref rid="rmv2163-bib-0102" ref-type="ref">
<sup>102</sup>
</xref>, <xref rid="rmv2163-bib-0103" ref-type="ref">
<sup>103</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Inhibition of inflammatory mucin release</td><td align="left" valign="top" rowspan="1" colspan="1">Human cell lines and primary cells. Inhibition of MUC5AC production</td><td align="left" valign="top" rowspan="1" colspan="1">Imamura et al, Ribeiro et al<xref rid="rmv2163-bib-0104" ref-type="ref">
<sup>104</sup>
</xref>, <xref rid="rmv2163-bib-0105" ref-type="ref">
<sup>105</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Modulated CXCL8 (IL&#x02010;8) production</td><td align="left" valign="top" rowspan="1" colspan="1">Human bronchial epithelial cells. Increased CXCL8 release</td><td align="left" valign="top" rowspan="1" colspan="1">Shinkai et al<xref rid="rmv2163-bib-0106" ref-type="ref">
<sup>106</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Reduced CXCL8 (IL&#x02010;8)</td><td align="left" valign="top" rowspan="1" colspan="1">Human trial. Roxithromycin reduced CXCL8 in nasal lavage in chronic rhinosinusitis, with clinical improvement</td><td align="left" valign="top" rowspan="1" colspan="1">Wallwork et al, Yamada et al<xref rid="rmv2163-bib-0107" ref-type="ref">
<sup>107</sup>
</xref>, <xref rid="rmv2163-bib-0108" ref-type="ref">
<sup>108</sup>
</xref>
</td></tr></tbody></table><table-wrap-foot id="rmv2163-ntgp-0002"><fn id="rmv2163-note-0002"><p>Abbreviations: CCL, C&#x02010;C motif ligand; CD, cluster of differentiation; CF, cystic fibrosis; CXCL, C&#x02010;X&#x02010;C motif ligand; DPB, diffuse panbronchiolitis; COX, cyclooxygenase; cPLA2, cytosolic phospholipase A2; ERK, extracellular signal&#x02010;regulated kinase; GM&#x02010;CSF, granulocyte&#x02010;macrophage colony&#x02010;stimulating factor (CSF2); IL, interleukin; MAPK, mitogen&#x02010;activated protein kinase; MCL1, myeloid cell leukaemia sequence 1; NALP3, NACHT, LRR, and PYD domains&#x02010;containing protein 3; PGE2, Prostaglandin E2; TGF&#x02010;beta, transforming growth factor beta.</p></fn></table-wrap-foot></table-wrap><fig fig-type="FIGURE" xml:lang="en" id="rmv2163-fig-0001" orientation="portrait" position="float"><label>FIGURE 1</label><caption><p>Anti&#x02010;viral and anti&#x02010;inflammatory effects of macrolides. Schematic showing major proposed mechanisms of azithromycin anti&#x02010;viral (green) and anti&#x02010;inflammatory or immunomodulatory (purple) activities. AZM, azithromycin; CRP, C&#x02010;reactive protein; CSF2, colony&#x02010;stimulating factor 2 (GM&#x02010;CSF); CXCL, C&#x02010;X&#x02010;C motif chemokine ligand; DC, dendritic cell; ICAM1, intracellular cell adhesion molecule 1; IFN, interferon; IL, interleukin; IRF3, Interferon Regulatory Factor 3; ISG, interferon&#x02010;stimulated gene; MDA5, melanoma differentiation&#x02010;associated protein 5; MPO, myeloperoxidase; MxA, myxoma resistance protein 1; NF&#x003ba;B, nuclear factor kappa B; NLRP3, nucleotide&#x02010;binding oligomerisation domain; phosTBK1, phosphorylated TANK&#x02010;binding kinase 1; PRR, pattern recognition receptor; RIG&#x02010;I, retinoic acid&#x02010;inducible gene I; RV, rhinovirus; Th17, type&#x02010;17 T&#x02010;helper; TLR, Toll&#x02010;like receptor; (s)TNF, (soluble) tissue necrosis factor</p></caption><graphic id="nlm-graphic-1" xlink:href="RMV-9999-e2163-g001"/></fig><sec id="rmv2163-sec-0010"><label>3.1</label><title>Immunomodulatory effects on phagocytes</title><p>AZM is rapidly absorbed after oral administration with a large volume of distribution<xref rid="rmv2163-bib-0109" ref-type="ref">
<sup>109</sup>
</xref> and a long serum half&#x02010;life of approximately 3&#x02009;days,<xref rid="rmv2163-bib-0110" ref-type="ref">
<sup>110</sup>
</xref> leading to a high and sustained tissue concentration. A striking feature of macrolides is that they can accumulate in host cells including epithelial cells and most particularly in phagocytes where they may concentrate 100&#x02010; to 3000&#x02010;fold in the lysosomes of phagocytes,<xref rid="rmv2163-bib-0077" ref-type="ref">
<sup>77</sup>
</xref>, <xref rid="rmv2163-bib-0081" ref-type="ref">
<sup>81</sup>
</xref>, <xref rid="rmv2163-bib-0111" ref-type="ref">
<sup>111</sup>
</xref>, <xref rid="rmv2163-bib-0112" ref-type="ref">
<sup>112</sup>
</xref> being subsequently retained intracellularly<xref rid="rmv2163-bib-0078" ref-type="ref">
<sup>78</sup>
</xref>, <xref rid="rmv2163-bib-0080" ref-type="ref">
<sup>80</sup>
</xref>, <xref rid="rmv2163-bib-0081" ref-type="ref">
<sup>81</sup>
</xref> and released when these cells die. Therefore typical AZM concentrations after one&#x02010;three 500&#x02009;mg oral doses may be 0.29 &#x003bc;M (0.22&#x02009;mg/L) in plasma, but 12 &#x003bc;M in lung tissue homogenate, 48 &#x003bc;M in bronchial washings and 260 &#x003bc;M in alveolar macrophages.<xref rid="rmv2163-bib-0113" ref-type="ref">
<sup>113</sup>
</xref> Several studies have observed initial stimulatory effects of AZM on immune and epithelial cells. Acutely, AZM stimulates neutrophil degranulation and phagocytosis&#x02010;associated oxidative burst, mediated via modulation of Erk1/2 signalling.<xref rid="rmv2163-bib-0079" ref-type="ref">
<sup>79</sup>
</xref> These initial stimulatory effects are followed by modulation of transcription factors activator protein (AP)&#x02010;1, nuclear factor kappa B (NF&#x003ba;B), inflammatory cytokine and mucin release, with overall anti&#x02010;inflammatory effects.</p><p>Many inflammatory cytokine levels are reduced by AZM, including IL&#x02010;6, IL&#x02010;8 (CXCL8), TNF<xref rid="rmv2163-bib-0114" ref-type="ref">
<sup>114</sup>
</xref> and GM&#x02010;CSF, as well as matrix metalloproteases MMP&#x02010;1, &#x02010;2, &#x02010;9, &#x02010;10 and &#x02010;13, and modulation of lipid metabolism and cell cycle pathways (Table <xref rid="rmv2163-tbl-0002" ref-type="table">2</xref>).<xref rid="rmv2163-bib-0070" ref-type="ref">
<sup>70</sup>
</xref>
</p><p>One pathway for macrolide immunomodulation is through binding to macrophilin&#x02010;12 inhibiting calcineurin and thus T cell activation, via the same mechanism as tacrolimus,<xref rid="rmv2163-bib-0029" ref-type="ref">
<sup>29</sup>
</xref> with consequent downstream inhibition of many immune cells including eosinophils and basophils.<xref rid="rmv2163-bib-0068" ref-type="ref">
<sup>68</sup>
</xref> Macrolides also inhibit mammalian target of rapamycin (mTOR) activity, also important in T cell activation and granulocyte differentiation,<xref rid="rmv2163-bib-0115" ref-type="ref">
<sup>115</sup>
</xref> suppressing cell proliferation and CD4 + T cell cytokine secretion.<xref rid="rmv2163-bib-0116" ref-type="ref">
<sup>116</sup>
</xref> A third pathway modulated by macrolides is activity of the transcription factors NF&#x003ba;B and AP&#x02010;1. AZM suppresses p65, a component of NF&#x003ba;B<xref rid="rmv2163-bib-0117" ref-type="ref">
<sup>117</sup>
</xref> and attenuates NF&#x003ba;B activation in lung epithelial cells.<xref rid="rmv2163-bib-0118" ref-type="ref">
<sup>118</sup>
</xref> This inhibition reduces epithelial cell IL&#x02010;8 production,<xref rid="rmv2163-bib-0067" ref-type="ref">
<sup>67</sup>
</xref>, <xref rid="rmv2163-bib-0118" ref-type="ref">
<sup>118</sup>
</xref> stromal cell proliferation<xref rid="rmv2163-bib-0066" ref-type="ref">
<sup>66</sup>
</xref> and macrophage expression of IL&#x02010;12p40<xref rid="rmv2163-bib-0119" ref-type="ref">
<sup>119</sup>
</xref> and, indirectly, IL&#x02010;1&#x003b2;.<xref rid="rmv2163-bib-0065" ref-type="ref">
<sup>65</sup>
</xref>, <xref rid="rmv2163-bib-0092" ref-type="ref">
<sup>92</sup>
</xref>
</p><p>In macrophages, AZM has several effects including attenuation of lipopolysaccharide&#x02010;induced pro&#x02010;inflammatory cytokines through inhibition of AP&#x02010;1, and increasing phagocytosis,<xref rid="rmv2163-bib-0120" ref-type="ref">
<sup>120</sup>
</xref> enhancing the resistance of lysosomes to oxidant challenge<xref rid="rmv2163-bib-0093" ref-type="ref">
<sup>93</sup>
</xref> and promoting M2 polarization of macrophages.<xref rid="rmv2163-bib-0089" ref-type="ref">
<sup>89</sup>
</xref>, <xref rid="rmv2163-bib-0090" ref-type="ref">
<sup>90</sup>
</xref>, <xref rid="rmv2163-bib-0119" ref-type="ref">
<sup>119</sup>
</xref> Macrolides including AZM can also increase the phagocytosis of apoptotic epithelial cells<xref rid="rmv2163-bib-0121" ref-type="ref">
<sup>121</sup>
</xref> and neutrophils by macrophages,<xref rid="rmv2163-bib-0087" ref-type="ref">
<sup>87</sup>
</xref> which can ameliorate inflammation.</p></sec><sec id="rmv2163-sec-0011"><label>3.2</label><title>Effects on other cell types</title><p>In vitro AZM modulated differentiation and maturation of dendritic cells towards a regulatory phenotype with increased phagocytic capacity,<xref rid="rmv2163-bib-0088" ref-type="ref">
<sup>88</sup>
</xref>, <xref rid="rmv2163-bib-0095" ref-type="ref">
<sup>95</sup>
</xref> with inhibited expression of CD40, CD86, MHCII and IL&#x02010;12.<xref rid="rmv2163-bib-0096" ref-type="ref">
<sup>96</sup>
</xref>, <xref rid="rmv2163-bib-0097" ref-type="ref">
<sup>97</sup>
</xref> Likewise AZM inhibited the cytotoxic function of natural killer cells through down regulation of perforin.<xref rid="rmv2163-bib-0098" ref-type="ref">
<sup>98</sup>
</xref>
</p><p>AZM may have anti&#x02010;inflammatory effects directly on epithelial cells, such as suppression of GM&#x02010;CSF release,<xref rid="rmv2163-bib-0099" ref-type="ref">
<sup>99</sup>
</xref> TNF,<xref rid="rmv2163-bib-0114" ref-type="ref">
<sup>114</sup>
</xref> inhibition of IL&#x02010;8 production<xref rid="rmv2163-bib-0118" ref-type="ref">
<sup>118</sup>
</xref> and modulation of the anti&#x02010;viral PRRs RIG&#x02010;I and MDA5.<xref rid="rmv2163-bib-0007" ref-type="ref">
<sup>7</sup>
</xref> AZM inhibition of AP&#x02010;1 activation reduces production of MUCA5C responsible for inflammation&#x02010;induced changes in airway mucus.<xref rid="rmv2163-bib-0071" ref-type="ref">
<sup>71</sup>
</xref>, <xref rid="rmv2163-bib-0122" ref-type="ref">
<sup>122</sup>
</xref> Macrolides inhibit airway epithelial cell mucus secretion<xref rid="rmv2163-bib-0123" ref-type="ref">
<sup>123</sup>
</xref> and directly inhibit neutrophil elastase.<xref rid="rmv2163-bib-0124" ref-type="ref">
<sup>124</sup>
</xref>, <xref rid="rmv2163-bib-0125" ref-type="ref">
<sup>125</sup>
</xref> Another effect of macrolides on airway epithelial cells observed in vitro is increased epithelial barrier integrity by alterations in tight junction proteins, including claudins.<xref rid="rmv2163-bib-0102" ref-type="ref">
<sup>102</sup>
</xref>, <xref rid="rmv2163-bib-0126" ref-type="ref">
<sup>126</sup>
</xref>
</p><p>Overall, macrolides have a number of inhibitory effects on the production of pro&#x02010;inflammatory cytokines from innate and adaptive immune cells, and most markedly on the accumulation, adhesion and apoptosis of pulmonary neutrophils.</p></sec></sec><sec id="rmv2163-sec-0012"><label>4</label><title>POTENTIAL CLINICAL UTILITY IN COVID&#x02010;19</title><p>Beyond its anti&#x02010;viral properties, the anti&#x02010;inflammatory effects of AZM may be clinically important in treating the cytokine storm which is a prominent feature of influenza A and of COVID&#x02010;19. An exuberant production of pro&#x02010;inflammatory cytokines including TNF, IL 1&#x003b2;, IL&#x02010;6, G&#x02010;CSF and IP&#x02010;10 are significantly increased in COVID&#x02010;19 disease,<xref rid="rmv2163-bib-0103" ref-type="ref">
<sup>103</sup>
</xref> and are associated with features of hemophagocytic lymphohistiocytosis<xref rid="rmv2163-bib-0127" ref-type="ref">
<sup>127</sup>
</xref> and interstitial mononuclear inflammatory infiltrates, dominated by lymphocytes,<xref rid="rmv2163-bib-0128" ref-type="ref">
<sup>128</sup>
</xref> and with poor clinical outcomes.<xref rid="rmv2163-bib-0103" ref-type="ref">
<sup>103</sup>
</xref> However, in contrast to influenza A, where this cytokine storm occurs early in disease, most COVID&#x02010;19 related deaths occur due to sudden, late respiratory failure, on average at day 14 after symptom onset,<xref rid="rmv2163-bib-0129" ref-type="ref">
<sup>129</sup>
</xref> by which point viral loads have markedly decreased. Severe COVID&#x02010;19 disease is associated with loss of alveolar macrophages<xref rid="rmv2163-bib-0130" ref-type="ref">
<sup>130</sup>
</xref> and an influx of pro&#x02010;inflammatory monocyte&#x02010;derived macrophages.<xref rid="rmv2163-bib-0131" ref-type="ref">
<sup>131</sup>
</xref>
</p><p>The importance of controlling this inflammation is demonstrated by the recent positive findings of the RECOVERY trial showing a significant mortality benefit with dexamethasone in patients with severe COVID&#x02010;19 disease and respiratory failure.<xref rid="rmv2163-bib-0132" ref-type="ref">
<sup>132</sup>
</xref> Interestingly, there was no benefit in those randomised at earlier disease stages, consistent with a lower degree of inflammation in these individuals, and suggesting other anti&#x02010;inflammatory approaches with fewer side effects might be valuable. The lag between symptom onset and severe disease provides a therapeutic window in which AZM anti&#x02010;inflammatory properties may reduce severe pulmonary inflammation, benefiting from the propensity of macrolides to accumulate in phagocytes,<xref rid="rmv2163-bib-0060" ref-type="ref">
<sup>60</sup>
</xref>, <xref rid="rmv2163-bib-0111" ref-type="ref">
<sup>111</sup>
</xref> which targets them specifically to the sites of pathology in COVID&#x02010;19.</p><p>It is understandable therefore, that more than 80 clinical trials have been designed to test AZM efficacy in COVID&#x02010;19 (Table <xref rid="rmv2163-supitem-0001" ref-type="supplementary-material">S1</xref>). These differ significantly from each other according to dosing regime, duration of therapy, whether being used in combination with hydroxychloroquine and, critically, according to the population being studied. Those recruiting in primary care will tend to study the anti&#x02010;viral effects in early disease, whilst those recruiting in secondary care will be studying more the anti&#x02010;inflammatory effects important in late disease. The first trial to publish results compared standard care with hydroxychloroquine (HCQ) 400&#x02009;mg twice daily or with HQC 400&#x02009;mg twice daily and AZM 500&#x02009;mg once daily for 7&#x02009;days in hospitalised patients with a median duration of symptoms of 7&#x02009;days prior to randomisation.<xref rid="rmv2163-bib-0133" ref-type="ref">
<sup>133</sup>
</xref> There was no reduction in symptoms or requirement for ventilation with either HCQ plus AZM compared with HCQ alone (odds ratio 0.82; 95% confidence interval 0.47&#x02010;1.43), but data from other populations, disease stages and without HCQ are urgently needed. If studies show clinical efficacy it will be essential to determine which populations benefit and what criteria to use as clinical indications for therapy. There is also a need for further human in vivo mechanistic studies to determine which of the manifold potential mechanisms are dominant in patients with disease.</p><p>AZM is generally well tolerated, the most common side effect being diarrhoea,<xref rid="rmv2163-bib-0029" ref-type="ref">
<sup>29</sup>
</xref> it is contraindicated in pregnancy and known hypersensitivity. Whilst there have been concerns about cardiovascular risk, huge epidemiological studies suggest these are very small effects (eg, 47 extra deaths/million prescriptions) or perhaps no effect when corrected for confounding,<xref rid="rmv2163-bib-0134" ref-type="ref">
<sup>134</sup>
</xref> and a Cochrane review of 183 trials found no evidence of an increase in cardiac disorders with macrolides (OR 0.87).<xref rid="rmv2163-bib-0135" ref-type="ref">
<sup>135</sup>
</xref> Concerns have been raised about the potential interactions between HCQ and AZM increasing risk of side effects. It should be used in caution in those receiving some other drugs including fluoroquinolones such as moxifloxacin and levofloxacin, and in patients with ongoing proarrhythmic conditions, and QT prolongation was more frequent in people with COVID&#x02010;19 receiving HCQ (14.6%) or the combination of HCQ and AZM (14.7%) than standard care (1.7%), an effect likely purely attributable to the HCQ.<xref rid="rmv2163-bib-0133" ref-type="ref">
<sup>133</sup>
</xref>
</p><p>Given the significant clinical utility of AZM as an antibiotic, the current rapid spread of antimicrobial resistance is of particular concern. Widespread use of AZM to treat viral infections runs an inevitable risk of increasing the development of drug&#x02010;resistant bacteria, and indeed there are good data that increasing rates of macrolide resistance in <italic>Streptococcus pneumoniae</italic> in the United States correlated closely with global sales of AZM, while in some regions such as China resistance rates approach 90% for <italic>Mycoplasma pneumoniae</italic> and nearly 100% for <italic>S. pneumoniae</italic>.<xref rid="rmv2163-bib-0110" ref-type="ref">
<sup>110</sup>
</xref> Resistance is a particularly high risk with macrolides due to several features including their long half&#x02010;life, the widespread use of the drug, and the high&#x02010;level macrolide, lincosamide and streptogramin (MLS<sub>B</sub>) resistance phenotype attributable to mutations in the <italic>erm</italic> gene and which are frequently associated with resistance to other classes of antibiotics on the same mobile genetic elements.<xref rid="rmv2163-bib-0110" ref-type="ref">
<sup>110</sup>
</xref> Therefore, it will be important to understand the potential anti&#x02010;viral and anti&#x02010;inflammatory properties of other novel macrolides which have been synthesised but do not have broad&#x02010;spectrum antibacterial properties and might therefore reduce development of resistance<xref rid="rmv2163-bib-0136" ref-type="ref">
<sup>136</sup>
</xref> and disruption to the natural microbiome.<xref rid="rmv2163-bib-0137" ref-type="ref">
<sup>137</sup>
</xref>
</p></sec><sec id="rmv2163-sec-0013"><label>5</label><title>CONCLUSIONS</title><p>As a therapeutic class, macrolides, and in particular AZM, with its long therapeutic half&#x02010;life, good safety profile and very strong evidence base in bacterial diseases are fascinating molecules. Macrolides undoubtedly have broad&#x02010;spectrum anti&#x02010;viral properties in vitro. AZM consistently emerges as a candidate molecule in anti&#x02010;viral drug screens against respiratory viruses, and there are tantalising hints of clinical efficacy in clinical studies to date. The additional anti&#x02010;inflammatory properties displayed by some macrolides, including AZM, may well prove to be clinically important in reducing immunopathology in some viral diseases, not least against the pandemic <italic>Betacoronaviruses</italic> in which activation of an over&#x02010;exuberant inflammatory cascade seems to be critical to mortality. However there is currently insufficient evidence to justify their use clinically, but rather, a clear mandate to perform well&#x02010;designed and conducted randomised trials in patients with chronic airways disorders and those with pandemic respiratory viruses including influenza A, SARS&#x02010;CoV&#x02010;2 and in future pandemics of novel coronaviruses which increasingly appear to be an inevitable prospect.</p></sec><sec sec-type="COI-statement" id="rmv2163-sec-0015"><title>CONFLICT OF INTEREST</title><p>M.E.O. None. T.S.C.H. has received unrestricted research grants from the Wellcome Trust (211050/Z/18/z, 211050/Z/18/A) and from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), the University of Oxford COVID&#x02010;19 Research Response Fund and from Pfizer to support conduct of a trial of azithromycin in COVID&#x02010;19.</p></sec><sec id="rmv2163-sec-0016"><title>AUTHOR CONTRIBUTIONS</title><p>Madeleine E. Oliver and Timothy S. C. Hinks jointly conceived the article, conducted the literature review and drafted the manuscript. All authors approved the final manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="rmv2163-supitem-0001"><caption><p>
<bold>Table S1</bold> Current clinical trials of azithromycin in SARS&#x02010;CoV&#x02010;2</p></caption><media xlink:href="RMV-9999-e2163-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="rmv2163-sec-0014"><title>ACKNOWLEDGEMENTS</title><p>This work was supported by grants from the Wellcome Trust (211050/Z/18/z, 211050/Z/18/A) and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) to T.S.C.H. The views expressed are those of the authors and not those of the NHS or NIHR. T.S.C.H. has received unrestricted research grants from the University of Oxford COVID&#x02010;19 Research Response Fund and from Pfizer to support conduct of a trial of azithromycin in COVID&#x02010;19.</p></ack><sec sec-type="data-availability" id="rmv2163-sec-0018"><title>DATA AVAILABILITY STATEMENT</title><p>Data sharing not applicable to this article as no datasets were generated or analysed during the current study.</p></sec><ref-list id="rmv2163-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="rmv2163-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="rmv2163-cit-0001">
<string-name>
<surname>Bright</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Hauske</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Azahomoerythromycin D derivative and intermediates therefor</article-title>. USA1984.</mixed-citation></ref><ref id="rmv2163-bib-0002"><label>2</label><mixed-citation publication-type="miscellaneous" id="rmv2163-cit-0002">
<string-name>
<surname>Kobrehel</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Radobolja</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Tamburasev</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Djokic</surname>
<given-names>S</given-names>
</string-name>. <article-title>11&#x02010;Aza&#x02010;10&#x02010;deoxo&#x02010;10&#x02010;dihydroerythromycin A and derivatives thereof as well as a process for their preparation</article-title>. USA1982.</mixed-citation></ref><ref id="rmv2163-bib-0003"><label>3</label><mixed-citation publication-type="book" id="rmv2163-cit-0003">
<collab collab-type="authors">World Health Organization</collab>
. <source xml:lang="en">Model List of Essential Medicines</source>. <edition designator="21">21st ed.</edition>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2019</year>.</mixed-citation></ref><ref id="rmv2163-bib-0004"><label>4</label><mixed-citation publication-type="book" id="rmv2163-cit-0004">
<string-name>
<surname>Sch&#x000f6;nfeld</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Kirst</surname>
<given-names>HA</given-names>
</string-name>. <source xml:lang="en">Effects of Macrolide Antibiotics on Ribosome Function</source>. <publisher-loc>Basel</publisher-loc>: <publisher-name>Birkh&#x000e4;user Verlag</publisher-name>; <year>2002</year>.</mixed-citation></ref><ref id="rmv2163-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="rmv2163-cit-0005">
<string-name>
<surname>Arabi</surname>
<given-names>YM</given-names>
</string-name>, <string-name>
<surname>Deeb</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Al&#x02010;Hameed</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Macrolides in critically ill patients with Middle East respiratory syndrome</article-title>. <source xml:lang="en">Int J Infect Dis</source>. <year>2019</year>;<volume>81</volume>:<fpage>184</fpage>&#x02010;<lpage>190</lpage>.<pub-id pub-id-type="pmid">30690213</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="rmv2163-cit-0006">
<collab collab-type="authors">C&#x02010;CRCEa</collab>
. <article-title>Global coalition to accelerate COVID&#x02010;19 clinical research in resource&#x02010;limited settings</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10233</issue>):<fpage>1322</fpage>&#x02010;<lpage>1325</lpage>.<pub-id pub-id-type="pmid">32247324</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="rmv2163-cit-0007">
<string-name>
<surname>Gielen</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Johnston</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>MR</given-names>
</string-name>. <article-title>Azithromycin induces anti&#x02010;viral responses in bronchial epithelial cells</article-title>. <source xml:lang="en">Eur Respir J</source>. <year>2010</year>;<volume>36</volume>(<issue>3</issue>):<fpage>646</fpage>&#x02010;<lpage>654</lpage>.<pub-id pub-id-type="pmid">20150207</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="rmv2163-cit-0008">
<string-name>
<surname>Schogler</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kopf</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>MR</given-names>
</string-name>, et al. <article-title>Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells</article-title>. <source xml:lang="en">Eur Respir J</source>. <year>2015</year>;<volume>45</volume>(<issue>2</issue>):<fpage>428</fpage>&#x02010;<lpage>439</lpage>.<pub-id pub-id-type="pmid">25359346</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="rmv2163-cit-0009">
<string-name>
<surname>Porter</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Watson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>
<given-names>LR</given-names>
</string-name>, et al. <article-title>Identification of novel macrolides with antibacterial, anti&#x02010;inflammatory and type I and III IFN&#x02010;augmenting activity in airway epithelium</article-title>. <source xml:lang="en">J Antimicrob Chemother</source>. <year>2016</year>;<volume>71</volume>(<issue>10</issue>):<fpage>2767</fpage>&#x02010;<lpage>2781</lpage>.<pub-id pub-id-type="pmid">27494903</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="rmv2163-cit-0010">
<string-name>
<surname>Doan</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hinterwirth</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Arzika</surname>
<given-names>AM</given-names>
</string-name>, et al. <article-title>Reduction of coronavirus burden with mass azithromycin distribution</article-title>. <source xml:lang="en">Clin Infect Dis</source>. <year>2020</year>;ciaa606. <ext-link ext-link-type="uri" xlink:href="doi:10.1093/cid/ciaa606">doi:10.1093/cid/ciaa606</ext-link>. Online ahead of print. </mixed-citation></ref><ref id="rmv2163-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="rmv2163-cit-0011">
<string-name>
<surname>Retallack</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Di Lullo</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Arias</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Zika virus cell tropism in the developing human brain and inhibition by azithromycin</article-title>. <source xml:lang="en">Proc Natl Acad Sci U S A</source>. <year>2016</year>;<volume>113</volume>(<issue>50</issue>):<fpage>14408</fpage>&#x02010;<lpage>14413</lpage>.<pub-id pub-id-type="pmid">27911847</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="rmv2163-cit-0012">
<string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>YQ</given-names>
</string-name>, et al. <article-title>Azithromycin protects against Zika virus infection by upregulating virus&#x02010;induced type I and III interferon responses</article-title>. <source xml:lang="en">Antimicrob Agents Chemother</source>. <year>2019</year>;<volume>63</volume>(<issue>12</issue>):<fpage>e00394</fpage>&#x02013;<lpage>19</lpage>. <ext-link ext-link-type="uri" xlink:href="doi:10.1128/AAC.00394-19">doi:10.1128/AAC.00394-19</ext-link>. </mixed-citation></ref><ref id="rmv2163-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="rmv2163-cit-0013">
<string-name>
<surname>Zeng</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Meng</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>Q</given-names>
</string-name>, et al. <article-title>Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo</article-title>. <source xml:lang="en">Int J Antimicrob Agents</source>. <year>2019</year>;<volume>53</volume>(<issue>4</issue>):<fpage>362</fpage>&#x02010;<lpage>369</lpage>.<pub-id pub-id-type="pmid">30599241</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="rmv2163-cit-0014">
<string-name>
<surname>Madrid</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Panchal</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Warren</surname>
<given-names>TK</given-names>
</string-name>, et al. <article-title>Evaluation of Ebola virus inhibitors for drug repurposing</article-title>. <source xml:lang="en">ACS Infect Dis</source>. <year>2015</year>;<volume>1</volume>(<issue>7</issue>):<fpage>317</fpage>&#x02010;<lpage>326</lpage>.<pub-id pub-id-type="pmid">27622822</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="rmv2163-cit-0015">
<string-name>
<surname>Kawamura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ichikado</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Takaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Eguchi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Anan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Suga</surname>
<given-names>M</given-names>
</string-name>. <article-title>Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score&#x02010;matching analysis of prospectively collected data at a single center</article-title>. <source xml:lang="en">Int J Antimicrob Agents</source>. <year>2018</year>;<volume>51</volume>(<issue>6</issue>):<fpage>918</fpage>&#x02010;<lpage>924</lpage>.<pub-id pub-id-type="pmid">29501821</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="rmv2163-cit-0016">
<string-name>
<surname>Lee</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>MCW</given-names>
</string-name>, et al. <article-title>Anti&#x02010;inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial</article-title>. <source xml:lang="en">Antiviral Res</source>. <year>2017</year>;<volume>144</volume>:<fpage>48</fpage>&#x02010;<lpage>56</lpage>.<pub-id pub-id-type="pmid">28535933</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="rmv2163-cit-0017">
<string-name>
<surname>Shinahara</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sawabuchi</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re&#x02010;infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis</article-title>. <source xml:lang="en">PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>7</issue>):<elocation-id>e70060</elocation-id>.<pub-id pub-id-type="pmid">23875018</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="rmv2163-cit-0018">
<string-name>
<surname>Hung</surname>
<given-names>IFN</given-names>
</string-name>, <string-name>
<surname>To</surname>
<given-names>KKW</given-names>
</string-name>, <string-name>
<surname>JFW</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Efficacy of clarithromycin&#x02010;naproxen&#x02010;oseltamivir combination in the treatment of patients hospitalized for influenza a(H3N2) infection: an open&#x02010;label randomized, controlled, phase IIb/III trial</article-title>. <source xml:lang="en">Chest</source>. <year>2017</year>;<volume>151</volume>(<issue>5</issue>):<fpage>1069</fpage>&#x02010;<lpage>1080</lpage>.<pub-id pub-id-type="pmid">27884765</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="rmv2163-cit-0019">
<string-name>
<surname>Higashi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Kubo</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yasuda</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nukiwa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yamaya</surname>
<given-names>M</given-names>
</string-name>. <article-title>Additional treatment with clarithromycin reduces fever duration in patients with influenza</article-title>. <source xml:lang="en">Respir Investig</source>. <year>2014</year>;<volume>52</volume>(<issue>5</issue>):<fpage>302</fpage>&#x02010;<lpage>309</lpage>.</mixed-citation></ref><ref id="rmv2163-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="rmv2163-cit-0020">
<string-name>
<surname>Walkey</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Wiener</surname>
<given-names>RS</given-names>
</string-name>. <article-title>Macrolide antibiotics and survival in patients with acute lung injury</article-title>. <source xml:lang="en">Chest</source>. <year>2012</year>;<volume>141</volume>(<issue>5</issue>):<fpage>1153</fpage>&#x02010;<lpage>1159</lpage>.<pub-id pub-id-type="pmid">22116799</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="rmv2163-cit-0021">
<string-name>
<surname>Tahan</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ozcan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Koc</surname>
<given-names>N</given-names>
</string-name>. <article-title>Clarithromycin in the treatment of RSV bronchiolitis: a double&#x02010;blind, randomised, placebo&#x02010;controlled trial</article-title>. <source xml:lang="en">Eur Respir J</source>. <year>2007</year>;<volume>29</volume>(<issue>1</issue>):<fpage>91</fpage>&#x02010;<lpage>97</lpage>.<pub-id pub-id-type="pmid">17050564</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="rmv2163-cit-0022">
<string-name>
<surname>Ninomiya</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fukui</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Imai</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Matsui</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Matsuoka</surname>
<given-names>K</given-names>
</string-name>. <article-title>Effect of maclorides on duration and resolution of symptoms and complication of pneumonia in children with influenza</article-title>. <source xml:lang="en">J Nippon Med Sch</source>. <year>2002</year>;<volume>69</volume>(<issue>1</issue>):<fpage>53</fpage>&#x02010;<lpage>57</lpage>.<pub-id pub-id-type="pmid">11847511</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="rmv2163-cit-0023">
<string-name>
<surname>McCallum</surname>
<given-names>GB</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Chatfield</surname>
<given-names>MD</given-names>
</string-name>, et al. <article-title>A single dose of azithromycin does not improve clinical outcomes of children hospitalised with bronchiolitis: a randomised, placebo&#x02010;controlled trial</article-title>. <source xml:lang="en">PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>9</issue>):<elocation-id>e74316</elocation-id>.<pub-id pub-id-type="pmid">24086334</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="rmv2163-cit-0024">
<string-name>
<surname>Martin&#x02010;Loeches</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Bermejo&#x02010;Martin</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Valles</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Macrolide&#x02010;based regimens in absence of bacterial co&#x02010;infection in critically ill H1N1 patients with primary viral pneumonia</article-title>. <source xml:lang="en">Intensive Care Med</source>. <year>2013</year>;<volume>39</volume>(<issue>4</issue>):<fpage>693</fpage>&#x02010;<lpage>702</lpage>.<pub-id pub-id-type="pmid">23344833</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="rmv2163-cit-0025">
<string-name>
<surname>Pinto</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Pitrez</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Luisi</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double&#x02010;blinded, and placebo&#x02010;controlled clinical trial</article-title>. <source xml:lang="en">J Pediatr</source>. <year>2012</year>;<volume>161</volume>(<issue>6</issue>):<fpage>1104</fpage>&#x02010;<lpage>1108</lpage>.<pub-id pub-id-type="pmid">22748516</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="rmv2163-cit-0026">
<string-name>
<surname>Kneyber</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>van Woensel</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Uijtendaal</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Uiterwaal</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Kimpen</surname>
<given-names>JL</given-names>
</string-name>. <article-title>Dutch antibiotics in RSVTRG. Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease: a randomized equivalence trial</article-title>. <source xml:lang="en">Pediatr Pulmonol</source>. <year>2008</year>;<volume>43</volume>(<issue>2</issue>):<fpage>142</fpage>&#x02010;<lpage>149</lpage>.<pub-id pub-id-type="pmid">18085694</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="rmv2163-cit-0027">
<string-name>
<surname>Kew</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Undela</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kotortsi</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Ferrara</surname>
<given-names>G</given-names>
</string-name>. <article-title>Macrolides for chronic asthma</article-title>. <source xml:lang="en">Cochrane Database Syst Rev</source>. <year>2015</year>;<volume>9</volume>:<elocation-id>CD002997</elocation-id>.</mixed-citation></ref><ref id="rmv2163-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="rmv2163-cit-0028">
<string-name>
<surname>Brusselle</surname>
<given-names>GG</given-names>
</string-name>, <string-name>
<surname>Vanderstichele</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jordens</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double&#x02010;blind placebo&#x02010;controlled trial</article-title>. <source xml:lang="en">Thorax</source>. <year>2013</year>;<volume>68</volume>(<issue>4</issue>):<fpage>322</fpage>&#x02010;<lpage>329</lpage>.<pub-id pub-id-type="pmid">23291349</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="rmv2163-cit-0029">
<string-name>
<surname>Gibson</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>IA</given-names>
</string-name>, <string-name>
<surname>Upham</surname>
<given-names>JW</given-names>
</string-name>, et al. <article-title>Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double&#x02010;blind, placebo&#x02010;controlled trial</article-title>. <source xml:lang="en">Lancet</source>. <year>2017</year>;<volume>390</volume>(<issue>10095</issue>):<fpage>659</fpage>&#x02010;<lpage>668</lpage>.<pub-id pub-id-type="pmid">28687413</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="rmv2163-cit-0030">
<string-name>
<surname>Johnston</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Blasi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Black</surname>
<given-names>PN</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Farrell</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Nieman</surname>
<given-names>RB</given-names>
</string-name>. <article-title>The effect of telithromycin in acute exacerbations of asthma</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2006</year>;<volume>354</volume>(<issue>15</issue>):<fpage>1589</fpage>&#x02010;<lpage>1600</lpage>.<pub-id pub-id-type="pmid">16611950</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="rmv2163-cit-0031">
<string-name>
<surname>Johnston</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Pattemore</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Sanderson</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Community study of role of viral infections in exacerbations of asthma in 9&#x02010;11 year old children</article-title>. <source xml:lang="en">BMJ</source>. <year>1995</year>;<volume>310</volume>(<issue>6989</issue>):<fpage>1225</fpage>&#x02010;<lpage>1229</lpage>.<pub-id pub-id-type="pmid">7767192</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="rmv2163-cit-0032">
<string-name>
<surname>Kelly</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Busse</surname>
<given-names>WW</given-names>
</string-name>. <article-title>Host immune responses to rhinovirus: mechanisms in asthma</article-title>. <source xml:lang="en">J Allergy Clin Immunol</source>. <year>2008</year>;<volume>122</volume>(<issue>4</issue>):<fpage>671</fpage>&#x02010;<lpage>682</lpage>. quiz 83&#x02010;4.<pub-id pub-id-type="pmid">19014757</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="rmv2163-cit-0033">
<string-name>
<surname>Taylor</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Leong</surname>
<given-names>LEX</given-names>
</string-name>, <string-name>
<surname>Mobegi</surname>
<given-names>FM</given-names>
</string-name>, et al. <article-title>Long&#x02010;term azithromycin reduces <italic>Haemophilus influenzae</italic> and increases antibiotic resistance in severe asthma</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>2019</year>;<volume>200</volume>(<issue>3</issue>):<fpage>309</fpage>&#x02010;<lpage>317</lpage>.<pub-id pub-id-type="pmid">30875247</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="rmv2163-cit-0034">
<string-name>
<surname>Taylor</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Ivey</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Rogers</surname>
<given-names>GB</given-names>
</string-name>, <collab collab-type="authors">Group ASR</collab>
. <article-title>Airway abundance of <italic>Haemophilus influenzae</italic> predicts response to azithromycin in adults with persistent uncontrolled asthma</article-title>. <source xml:lang="en">Eur Respir J</source>. <year>2020</year>;2000194. <ext-link ext-link-type="uri" xlink:href="doi:10.1183/13993003.00194-2020">doi:10.1183/13993003.00194-2020</ext-link>. </mixed-citation></ref><ref id="rmv2163-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="rmv2163-cit-0035">
<string-name>
<surname>Sajjan</surname>
<given-names>US</given-names>
</string-name>, <string-name>
<surname>Jia</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Newcomb</surname>
<given-names>DC</given-names>
</string-name>, et al. <article-title>
<italic>H. influenzae</italic> potentiates airway epithelial cell responses to rhinovirus by increasing ICAM&#x02010;1 and TLR3 expression</article-title>. <source xml:lang="en">FASEB J</source>. <year>2006</year>;<volume>20</volume>(<issue>12</issue>):<fpage>2121</fpage>&#x02010;<lpage>2123</lpage>.<pub-id pub-id-type="pmid">16914605</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="rmv2163-cit-0036">
<string-name>
<surname>Jang</surname>
<given-names>YJ</given-names>
</string-name>, <string-name>
<surname>Kwon</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>BJ</given-names>
</string-name>. <article-title>Effect of clarithromycin on rhinovirus&#x02010;16 infection in A549 cells</article-title>. <source xml:lang="en">Eur Respir J</source>. <year>2006</year>;<volume>27</volume>(<issue>1</issue>):<fpage>12</fpage>&#x02010;<lpage>19</lpage>.<pub-id pub-id-type="pmid">16387930</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="rmv2163-cit-0037">
<string-name>
<surname>Stroher</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>DiCaro</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Severe acute respiratory syndrome&#x02010;related coronavirus is inhibited by interferon&#x02010;alpha</article-title>. <source xml:lang="en">J Infect Dis</source>. <year>2004</year>;<volume>189</volume>(<issue>7</issue>):<fpage>1164</fpage>&#x02010;<lpage>1167</lpage>.<pub-id pub-id-type="pmid">15031783</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0038"><label>38</label><mixed-citation publication-type="miscellaneous" id="rmv2163-cit-0038">
<string-name>
<surname>Lokugamage</surname>
<given-names>KG</given-names>
</string-name>, <string-name>
<surname>Hage</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schindewolf</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rajsbaum</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Menachery</surname>
<given-names>VD.</given-names>
</string-name>
<article-title>SARS&#x02010;CoV&#x02010;2 is sensitive to type I interferon pretreatment. bioRxiv</article-title>. <year>2020</year>.</mixed-citation></ref><ref id="rmv2163-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="rmv2163-cit-0039">
<string-name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yamaya</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sekizawa</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>2002</year>;<volume>165</volume>(<issue>8</issue>):<fpage>1113</fpage>&#x02010;<lpage>1118</lpage>.<pub-id pub-id-type="pmid">11956054</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="rmv2163-cit-0040">
<string-name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yamaya</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sekizawa</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Bafilomycin A(1) inhibits rhinovirus infection in human airway epithelium: effects on endosome and ICAM&#x02010;1</article-title>. <source xml:lang="en">Am J Physiol Lung Cell Mol Physiol</source>. <year>2001</year>;<volume>280</volume>(<issue>6</issue>):<fpage>L1115</fpage>&#x02010;<lpage>L1127</lpage>.<pub-id pub-id-type="pmid">11350790</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="rmv2163-cit-0041">
<string-name>
<surname>Miyamoto</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hasegawa</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sriwilaijaroen</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Clarithromycin inhibits progeny virus production from human influenza virus&#x02010;infected host cells</article-title>. <source xml:lang="en">Biol Pharm Bull</source>. <year>2008</year>;<volume>31</volume>(<issue>2</issue>):<fpage>217</fpage>&#x02010;<lpage>222</lpage>.<pub-id pub-id-type="pmid">18239276</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="rmv2163-cit-0042">
<string-name>
<surname>Yamaya</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shinya</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hatachi</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells</article-title>. <source xml:lang="en">J Pharmacol Exp Ther</source>. <year>2010</year>;<volume>333</volume>(<issue>1</issue>):<fpage>81</fpage>&#x02010;<lpage>90</lpage>.<pub-id pub-id-type="pmid">20040578</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="rmv2163-cit-0043">
<string-name>
<surname>Tran</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Sugamata</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hirose</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Azithromycin, a 15&#x02010;membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process</article-title>. <source xml:lang="en">J Antibiot (Tokyo)</source>. <year>2019</year>;<volume>72</volume>(<issue>10</issue>):<fpage>759</fpage>&#x02010;<lpage>768</lpage>.<pub-id pub-id-type="pmid">31300721</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="rmv2163-cit-0044">
<string-name>
<surname>Sato</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Suga</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Akaike</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Therapeutic effect of erythromycin on influenza virus&#x02010;induced lung injury in mice</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>1998</year>;<volume>157</volume>(<issue>3 Pt 1</issue>):<fpage>853</fpage>&#x02010;<lpage>857</lpage>.<pub-id pub-id-type="pmid">9517602</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="rmv2163-cit-0045">
<string-name>
<surname>Sugamata</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sugawara</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nagao</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Leucomycin A3, a 16&#x02010;membered macrolide antibiotic, inhibits influenza A virus infection and disease progression</article-title>. <source xml:lang="en">J Antibiot (Tokyo)</source>. <year>2014</year>;<volume>67</volume>(<issue>3</issue>):<fpage>213</fpage>&#x02010;<lpage>222</lpage>.<pub-id pub-id-type="pmid">24496145</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="rmv2163-cit-0046">
<string-name>
<surname>Fage</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pizzorno</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rheaume</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Abed</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Boivin</surname>
<given-names>G</given-names>
</string-name>. <article-title>The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus</article-title>. <source xml:lang="en">J Med Virol</source>. <year>2017</year>;<volume>89</volume>(<issue>12</issue>):<fpage>2239</fpage>&#x02010;<lpage>2243</lpage>.<pub-id pub-id-type="pmid">28792077</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="rmv2163-cit-0047">
<string-name>
<surname>Beigelman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mikols</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Gunsten</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Brody</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Walter</surname>
<given-names>MJ</given-names>
</string-name>. <article-title>Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis</article-title>. <source xml:lang="en">Respir Res</source>. <year>2010</year>;<volume>11</volume>:<elocation-id>90</elocation-id>.<pub-id pub-id-type="pmid">20591166</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="rmv2163-cit-0048">
<string-name>
<surname>de Wit</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>van Doremalen</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Falzarano</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Munster</surname>
<given-names>VJ</given-names>
</string-name>. <article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title>. <source xml:lang="en">Nat Rev Microbiol</source>. <year>2016</year>;<volume>14</volume>(<issue>8</issue>):<fpage>523</fpage>&#x02010;<lpage>534</lpage>.<pub-id pub-id-type="pmid">27344959</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="rmv2163-cit-0049">
<string-name>
<surname>Beigel</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Tomashek</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Dodd</surname>
<given-names>LE</given-names>
</string-name>, et al. <article-title>Remdesivir for the treatment of Covid&#x02010;19&#x02014;preliminary report</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>;NEJMoa2007764. <ext-link ext-link-type="uri" xlink:href="doi:10.1056/NEJMoa2007764">doi:10.1056/NEJMoa2007764</ext-link>. </mixed-citation></ref><ref id="rmv2163-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="rmv2163-cit-0050">
<string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Du</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Remdesivir in adults with severe COVID&#x02010;19: a randomised, double&#x02010;blind, placebo&#x02010;controlled, multicentre trial</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10236</issue>):<fpage>1569</fpage>&#x02010;<lpage>1578</lpage>.<pub-id pub-id-type="pmid">32423584</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="rmv2163-cit-0051">
<string-name>
<surname>Nabirotchkin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Peluffo</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Bouaziz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>D</given-names>
</string-name>. <article-title>Focusing on the unfolded protein response and autophagy related pathways to reposition common approved drugs against COVID&#x02010;19</article-title>. <source xml:lang="en">Preprints</source>. <year>2020</year><ext-link ext-link-type="uri" xlink:href="doi:10.20944/preprints202003.0302.v1">doi:10.20944/preprints202003.0302.v1</ext-link>. </mixed-citation></ref><ref id="rmv2163-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="rmv2163-cit-0052">
<string-name>
<surname>Renna</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schaffner</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection</article-title>. <source xml:lang="en">J Clin Invest</source>. <year>2011</year>;<volume>121</volume>(<issue>9</issue>):<fpage>3554</fpage>&#x02010;<lpage>3563</lpage>.<pub-id pub-id-type="pmid">21804191</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="rmv2163-cit-0053">
<string-name>
<surname>Andreani</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Le Bideau</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Duflot</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>In vitro testing of combined hydroxychloroquine and azithromycin on SARS&#x02010;CoV&#x02010;2 shows synergistic effect</article-title>. <source xml:lang="en">Microb Pathog</source>. <year>2020</year>;<volume>145</volume>:<elocation-id>104228</elocation-id>.<pub-id pub-id-type="pmid">32344177</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="rmv2163-cit-0054">
<string-name>
<surname>Gautret</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lagier</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Parola</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Hydroxychloroquine and azithromycin as a treatment of COVID&#x02010;19: results of an open&#x02010;label non&#x02010;randomized clincial trial</article-title>. <source xml:lang="en">Int J of Antimicrobial Agents</source>. <year>2020</year>;<volume>56</volume>:<elocation-id>105949</elocation-id>.</mixed-citation></ref><ref id="rmv2163-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="rmv2163-cit-0055">
<string-name>
<surname>Mercuro</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Yen</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Shim</surname>
<given-names>DJ</given-names>
</string-name>, et al. <article-title>Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID&#x02010;19)</article-title>. <source xml:lang="en">JAMA Cardiol</source>. <year>2020</year>;e201834. <ext-link ext-link-type="uri" xlink:href="doi:10.1001/jamacardio.2020.1834">doi:10.1001/jamacardio.2020.1834</ext-link>. </mixed-citation></ref><ref id="rmv2163-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="rmv2163-cit-0056">
<string-name>
<surname>Maisonnasse</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Guedj</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Contreras</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Hydroxychloroquine use against SARS&#x02010;CoV&#x02010;2 infection in non&#x02010;human primates</article-title>. <source xml:lang="en">Nature</source>. <year>2020</year><ext-link ext-link-type="uri" xlink:href="doi:10.1038/s41586-020-2558-4">doi:10.1038/s41586-020-2558-4</ext-link>. </mixed-citation></ref><ref id="rmv2163-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="rmv2163-cit-0057">
<string-name>
<surname>Buonaguro</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Ascierto</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Morse</surname>
<given-names>GD</given-names>
</string-name>, et al. <article-title>Covid&#x02010;19: time for a paradigm change</article-title>. <source xml:lang="en">Rev Med Virol</source>. <year>2020</year>;<elocation-id>e2134</elocation-id>
<ext-link ext-link-type="uri" xlink:href="doi:10.1002/rmv.2134">doi:10.1002/rmv.2134</ext-link>. <pub-id pub-id-type="pmid">32618072</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="rmv2163-cit-0058">
<string-name>
<surname>Albert</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Connett</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bailey</surname>
<given-names>WC</given-names>
</string-name>, et al. <article-title>Azithromycin for prevention of exacerbations of COPD</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2011</year>;<volume>365</volume>(<issue>8</issue>):<fpage>689</fpage>&#x02010;<lpage>698</lpage>.<pub-id pub-id-type="pmid">21864166</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="rmv2163-cit-0059">
<string-name>
<surname>Vos</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Vanaudenaerde</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Verleden</surname>
<given-names>SE</given-names>
</string-name>, et al. <article-title>A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation</article-title>. <source xml:lang="en">Eur Respir J</source>. <year>2011</year>;<volume>37</volume>(<issue>1</issue>):<fpage>164</fpage>&#x02010;<lpage>172</lpage>.<pub-id pub-id-type="pmid">20562124</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="rmv2163-cit-0060">
<string-name>
<surname>Altenburg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>de Graaff</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>van der Werf</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Boersma</surname>
<given-names>WG</given-names>
</string-name>. <article-title>Immunomodulatory effects of macrolide antibiotics&#x02014;part 1: biological mechanisms</article-title>. <source xml:lang="en">Respiration</source>. <year>2011</year>;<volume>81</volume>(<issue>1</issue>):<fpage>67</fpage>&#x02010;<lpage>74</lpage>.<pub-id pub-id-type="pmid">20733281</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="rmv2163-cit-0061">
<string-name>
<surname>Hui</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>RH</given-names>
</string-name>. <article-title>The effects of azithromycin on patients with diffuse panbronchiolitis: a retrospective study of 29 cases</article-title>. <source xml:lang="en">J Thorac Dis</source>. <year>2013</year>;<volume>5</volume>(<issue>5</issue>):<fpage>613</fpage>&#x02010;<lpage>617</lpage>.<pub-id pub-id-type="pmid">24255774</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="rmv2163-cit-0062">
<string-name>
<surname>Kudoh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Azuma</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Izumi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ando</surname>
<given-names>M</given-names>
</string-name>. <article-title>Improvement of survival in patients with diffuse panbronchiolitis treated with low&#x02010;dose erythromycin</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>1998</year>;<volume>157</volume>(<issue>6 Pt 1</issue>):<fpage>1829</fpage>&#x02010;<lpage>1832</lpage>.<pub-id pub-id-type="pmid">9620913</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="rmv2163-cit-0063">
<string-name>
<surname>Nagai</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Shishido</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yoneda</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Yamaguchi</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Tamura</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kurashima</surname>
<given-names>A</given-names>
</string-name>. <article-title>Long&#x02010;term low&#x02010;dose administration of erythromycin to patients with diffuse panbronchiolitis</article-title>. <source xml:lang="en">Respiration</source>. <year>1991</year>;<volume>58</volume>(<issue>3&#x02013;4</issue>):<fpage>145</fpage>&#x02010;<lpage>149</lpage>.<pub-id pub-id-type="pmid">1745845</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="rmv2163-cit-0064">
<string-name>
<surname>Weng</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>XQ</given-names>
</string-name>, et al. <article-title>Azithromycin treats diffuse panbronchiolitis by targeting T cells via inhibition of mTOR pathway</article-title>. <source xml:lang="en">Biomed Pharmacother</source>. <year>2019</year>;<volume>110</volume>:<fpage>440</fpage>&#x02010;<lpage>448</lpage>.<pub-id pub-id-type="pmid">30530046</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="rmv2163-cit-0065">
<string-name>
<surname>Bosnar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kragol</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kostrun</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>N&#x02032;&#x02010;substituted&#x02010;2&#x02032;&#x02010;O,3&#x02032;&#x02010;N&#x02010;carbonimidoyl bridged macrolides: novel anti&#x02010;inflammatory macrolides without antimicrobial activity</article-title>. <source xml:lang="en">J Med Chem</source>. <year>2012</year>;<volume>55</volume>(<issue>13</issue>):<fpage>6111</fpage>&#x02010;<lpage>6123</lpage>.<pub-id pub-id-type="pmid">22697905</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="rmv2163-cit-0066">
<string-name>
<surname>Miller</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Selzman</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Shames</surname>
<given-names>BD</given-names>
</string-name>, <string-name>
<surname>Barton</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Harken</surname>
<given-names>AH</given-names>
</string-name>. <article-title>
<italic>Chlamydia pneumoniae</italic> activates nuclear factor kappaB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation</article-title>. <source xml:lang="en">J Surg Res</source>. <year>2000</year>;<volume>90</volume>(<issue>1</issue>):<fpage>76</fpage>&#x02010;<lpage>81</lpage>.<pub-id pub-id-type="pmid">10781378</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="rmv2163-cit-0067">
<string-name>
<surname>Srivastava</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Vardhan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Bhengraj</surname>
<given-names>AR</given-names>
</string-name>, et al. <article-title>Azithromycin treatment modulates the extracellular signal&#x02010;regulated kinase mediated pathway and inhibits inflammatory cytokines and chemokines in epithelial cells from infertile women with recurrent <italic>Chlamydia trachomatis</italic> infection</article-title>. <source xml:lang="en">DNA Cell Biol</source>. <year>2011</year>;<volume>30</volume>(<issue>8</issue>):<fpage>545</fpage>&#x02010;<lpage>554</lpage>.<pub-id pub-id-type="pmid">21438755</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="rmv2163-cit-0068">
<string-name>
<surname>Rolfe</surname>
<given-names>FG</given-names>
</string-name>, <string-name>
<surname>Valentine</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Sewell</surname>
<given-names>WA</given-names>
</string-name>. <article-title>Cyclosporin A and FK506 reduce interleukin&#x02010;5 mRNA abundance by inhibiting gene transcription</article-title>. <source xml:lang="en">Am J Respir Cell Mol Biol</source>. <year>1997</year>;<volume>17</volume>(<issue>2</issue>):<fpage>243</fpage>&#x02010;<lpage>250</lpage>.<pub-id pub-id-type="pmid">9271313</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="rmv2163-cit-0069">
<string-name>
<surname>Miyazaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zaitsu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Honjo</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ishii</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hamasaki</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Macrolide antibiotics inhibit prostaglandin E2 synthesis and mRNA expression of prostaglandin synthetic enzymes in human leukocytes</article-title>. <source xml:lang="en">Prostaglandins Leukot Essent Fatty Acids</source>. <year>2003</year>;<volume>69</volume>(<issue>4</issue>):<fpage>229</fpage>&#x02010;<lpage>235</lpage>.<pub-id pub-id-type="pmid">12907132</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="rmv2163-cit-0070">
<string-name>
<surname>Vanaudenaerde</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Wuyts</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Geudens</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Macrolides inhibit IL17&#x02010;induced IL8 and 8&#x02010;isoprostane release from human airway smooth muscle cells</article-title>. <source xml:lang="en">Am J Transplant</source>. <year>2007</year>;<volume>7</volume>(<issue>1</issue>):<fpage>76</fpage>&#x02010;<lpage>82</lpage>.<pub-id pub-id-type="pmid">17061983</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="rmv2163-cit-0071">
<string-name>
<surname>Nie</surname>
<given-names>YC</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>PB</given-names>
</string-name>, et al. <article-title>Naringin attenuates EGF&#x02010;induced MUC5AC secretion in A549 cells by suppressing the cooperative activities of MAPKs&#x02010;AP&#x02010;1 and IKKs&#x02010;IkappaB&#x02010;NF&#x02010;kappaB signaling pathways</article-title>. <source xml:lang="en">Eur J Pharmacol</source>. <year>2012</year>;<volume>690</volume>(<issue>1&#x02013;3</issue>):<fpage>207</fpage>&#x02010;<lpage>213</lpage>.<pub-id pub-id-type="pmid">22766066</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="rmv2163-cit-0072">
<string-name>
<surname>Takizawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Desaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ohtoshi</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Erythromycin and clarithromycin attenuate cytokine&#x02010;induced endothelin&#x02010;1 expression in human bronchial epithelial cells</article-title>. <source xml:lang="en">Eur Respir J</source>. <year>1998</year>;<volume>12</volume>(<issue>1</issue>):<fpage>57</fpage>&#x02010;<lpage>63</lpage>.<pub-id pub-id-type="pmid">9701415</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="rmv2163-cit-0073">
<string-name>
<surname>Tyteca</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schanck</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dufrene</surname>
<given-names>YF</given-names>
</string-name>, et al. <article-title>The macrolide antibiotic azithromycin interacts with lipids and affects membrane organization and fluidity: studies on Langmuir&#x02010;Blodgett monolayers, liposomes and J774 macrophages</article-title>. <source xml:lang="en">J Membr Biol</source>. <year>2003</year>;<volume>192</volume>(<issue>3</issue>):<fpage>203</fpage>&#x02010;<lpage>215</lpage>.<pub-id pub-id-type="pmid">12820665</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="rmv2163-cit-0074">
<string-name>
<surname>Tyteca</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Van Der Smissen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mettlen</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid&#x02010;phase and receptor&#x02010;mediated endocytosis, but does not impair phagocytosis in J774 macrophages</article-title>. <source xml:lang="en">Exp Cell Res</source>. <year>2002</year>;<volume>281</volume>(<issue>1</issue>):<fpage>86</fpage>&#x02010;<lpage>100</lpage>.<pub-id pub-id-type="pmid">12441132</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="rmv2163-cit-0075">
<string-name>
<surname>Gerbaux</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Van Bambeke</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Montenez</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Piret</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Morlighem</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Tulkens</surname>
<given-names>PM</given-names>
</string-name>. <article-title>Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation</article-title>. <source xml:lang="en">FEBS Lett</source>. <year>1996</year>;<volume>394</volume>(<issue>3</issue>):<fpage>307</fpage>&#x02010;<lpage>310</lpage>.<pub-id pub-id-type="pmid">8830663</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="rmv2163-cit-0076">
<string-name>
<surname>Ikeda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hirayama</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hirota</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Asa</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Seki</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Drug&#x02010;induced phospholipidosis is caused by blockade of mannose 6&#x02010;phosphate receptor&#x02010;mediated targeting of lysosomal enzymes</article-title>. <source xml:lang="en">Biochem Biophys Res Commun</source>. <year>2008</year>;<volume>377</volume>(<issue>1</issue>):<fpage>268</fpage>&#x02010;<lpage>274</lpage>.<pub-id pub-id-type="pmid">18840403</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="rmv2163-cit-0077">
<string-name>
<surname>Wilms</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Touw</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Heijerman</surname>
<given-names>HG</given-names>
</string-name>. <article-title>Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long&#x02010;term therapy in patients with cystic fibrosis</article-title>. <source xml:lang="en">Ther Drug Monit</source>. <year>2006</year>;<volume>28</volume>(<issue>2</issue>):<fpage>219</fpage>&#x02010;<lpage>225</lpage>.<pub-id pub-id-type="pmid">16628134</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="rmv2163-cit-0078">
<string-name>
<surname>Wildfeuer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Laufen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zimmermann</surname>
<given-names>T</given-names>
</string-name>. <article-title>Distribution of orally administered azithromycin in various blood compartments</article-title>. <source xml:lang="en">Int J Clin Pharmacol Ther</source>. <year>1994</year>;<volume>32</volume>(<issue>7</issue>):<fpage>356</fpage>&#x02010;<lpage>360</lpage>.<pub-id pub-id-type="pmid">7952797</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="rmv2163-cit-0079">
<string-name>
<surname>Ishimoto</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Mukae</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sakamoto</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide&#x02010;1 or lipopolysaccharide in NCI&#x02010;H292 cells compared with azithromycin and clarithromycin</article-title>. <source xml:lang="en">J Antimicrob Chemother</source>. <year>2009</year>;<volume>63</volume>(<issue>1</issue>):<fpage>109</fpage>&#x02010;<lpage>114</lpage>.<pub-id pub-id-type="pmid">18931390</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="rmv2163-cit-0080">
<string-name>
<surname>Bosnar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kelneric</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Munic</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Erakovic</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Parnham</surname>
<given-names>MJ</given-names>
</string-name>. <article-title>Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin</article-title>. <source xml:lang="en">Antimicrob Agents Chemother</source>. <year>2005</year>;<volume>49</volume>(<issue>6</issue>):<fpage>2372</fpage>&#x02010;<lpage>2377</lpage>.<pub-id pub-id-type="pmid">15917536</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="rmv2163-cit-0081">
<string-name>
<surname>Capitano</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Mattoes</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Shore</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Steady&#x02010;state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults</article-title>. <source xml:lang="en">Chest</source>. <year>2004</year>;<volume>125</volume>(<issue>3</issue>):<fpage>965</fpage>&#x02010;<lpage>973</lpage>.<pub-id pub-id-type="pmid">15006955</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="rmv2163-cit-0082">
<string-name>
<surname>Tsai</surname>
<given-names>WC</given-names>
</string-name>, <string-name>
<surname>Rodriguez</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>KS</given-names>
</string-name>, et al. <article-title>Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>2004</year>;<volume>170</volume>(<issue>12</issue>):<fpage>1331</fpage>&#x02010;<lpage>1339</lpage>.<pub-id pub-id-type="pmid">15361366</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="rmv2163-cit-0083">
<string-name>
<surname>Culic</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Erakovic</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Cepelak</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects</article-title>. <source xml:lang="en">Eur J Pharmacol</source>. <year>2002</year>;<volume>450</volume>(<issue>3</issue>):<fpage>277</fpage>&#x02010;<lpage>289</lpage>.<pub-id pub-id-type="pmid">12208321</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="rmv2163-cit-0084">
<string-name>
<surname>Tsai</surname>
<given-names>WC</given-names>
</string-name>, <string-name>
<surname>Standiford</surname>
<given-names>TJ</given-names>
</string-name>. <article-title>Immunomodulatory effects of macrolides in the lung: lessons from in&#x02010;vitro and in&#x02010;vivo models</article-title>. <source xml:lang="en">Curr Pharm des</source>. <year>2004</year>;<volume>10</volume>(<issue>25</issue>):<fpage>3081</fpage>&#x02010;<lpage>3093</lpage>.<pub-id pub-id-type="pmid">15544499</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="rmv2163-cit-0085">
<string-name>
<surname>Nozoe</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Aida</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fukuda</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sanui</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nishimura</surname>
<given-names>F</given-names>
</string-name>. <article-title>Mechanisms of the macrolide&#x02010;induced inhibition of superoxide generation by neutrophils</article-title>. <source xml:lang="en">Inflammation</source>. <year>2016</year>;<volume>39</volume>(<issue>3</issue>):<fpage>1039</fpage>&#x02010;<lpage>1048</lpage>.<pub-id pub-id-type="pmid">26983705</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="rmv2163-cit-0086">
<string-name>
<surname>Simpson</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Powell</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Boyle</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>
<given-names>PG</given-names>
</string-name>. <article-title>Clarithromycin targets neutrophilic airway inflammation in refractory asthma</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>2008</year>;<volume>177</volume>(<issue>2</issue>):<fpage>148</fpage>&#x02010;<lpage>155</lpage>.<pub-id pub-id-type="pmid">17947611</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="rmv2163-cit-0087">
<string-name>
<surname>Yamaryo</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Oishi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yoshimine</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Tsuchihashi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Matsushima</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nagatake</surname>
<given-names>T</given-names>
</string-name>. <article-title>Fourteen&#x02010;member macrolides promote the phosphatidylserine receptor&#x02010;dependent phagocytosis of apoptotic neutrophils by alveolar macrophages</article-title>. <source xml:lang="en">Antimicrob Agents Chemother</source>. <year>2003</year>;<volume>47</volume>(<issue>1</issue>):<fpage>48</fpage>&#x02010;<lpage>53</lpage>.<pub-id pub-id-type="pmid">12499168</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="rmv2163-cit-0088">
<string-name>
<surname>Polancec</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Munic Kos</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Banjanac</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Azithromycin drives in vitro GM&#x02010;CSF/IL&#x02010;4&#x02010;induced differentiation of human blood monocytes toward dendritic&#x02010;like cells with regulatory properties</article-title>. <source xml:lang="en">J Leukoc Biol</source>. <year>2012</year>;<volume>91</volume>(<issue>2</issue>):<fpage>229</fpage>&#x02010;<lpage>243</lpage>.<pub-id pub-id-type="pmid">22131344</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="rmv2163-cit-0089">
<string-name>
<surname>Murphy</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Sundareshan</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Cory</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Hayes</surname>
<given-names>D</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Anstead</surname>
<given-names>MI</given-names>
</string-name>, <string-name>
<surname>Feola</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Azithromycin alters macrophage phenotype</article-title>. <source xml:lang="en">J Antimicrob Chemother</source>. <year>2008</year>;<volume>61</volume>(<issue>3</issue>):<fpage>554</fpage>&#x02010;<lpage>560</lpage>.<pub-id pub-id-type="pmid">18230686</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="rmv2163-cit-0090">
<string-name>
<surname>Legssyer</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Huaux</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lebacq</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice</article-title>. <source xml:lang="en">Respir Res</source>. <year>2006</year>;<volume>7</volume>:<elocation-id>134</elocation-id>.<pub-id pub-id-type="pmid">17064416</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="rmv2163-cit-0091">
<string-name>
<surname>Bosnar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bosnjak</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Cuzic</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Azithromycin and clarithromycin inhibit lipopolysaccharide&#x02010;induced murine pulmonary neutrophilia mainly through effects on macrophage&#x02010;derived granulocyte&#x02010;macrophage colony&#x02010;stimulating factor and interleukin&#x02010;1beta</article-title>. <source xml:lang="en">J Pharmacol Exp Ther</source>. <year>2009</year>;<volume>331</volume>(<issue>1</issue>):<fpage>104</fpage>&#x02010;<lpage>113</lpage>.<pub-id pub-id-type="pmid">19633061</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="rmv2163-cit-0092">
<string-name>
<surname>Lendermon</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Coon</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Bednash</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Weathington</surname>
<given-names>NM</given-names>
</string-name>, <string-name>
<surname>McDyer</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Mallampalli</surname>
<given-names>RK</given-names>
</string-name>. <article-title>Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome&#x02010;dependent inflammation</article-title>. <source xml:lang="en">Respir Res</source>. <year>2017</year>;<volume>18</volume>(<issue>1</issue>):<elocation-id>131</elocation-id>.<pub-id pub-id-type="pmid">28659178</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="rmv2163-cit-0093">
<string-name>
<surname>Persson</surname>
<given-names>HL</given-names>
</string-name>, <string-name>
<surname>Vainikka</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Sege</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wennerstrom</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Dam&#x02010;Larsen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Persson</surname>
<given-names>J</given-names>
</string-name>. <article-title>Leaky lysosomes in lung transplant macrophages: azithromycin prevents oxidative damage</article-title>. <source xml:lang="en">Respir Res</source>. <year>2012</year>;<volume>13</volume>:<fpage>83</fpage>.<pub-id pub-id-type="pmid">23006592</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="rmv2163-cit-0094">
<string-name>
<surname>Kurdowska</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Noble</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Griffith</surname>
<given-names>DE</given-names>
</string-name>. <article-title>The effect of azithromycin and clarithromycin on ex vivo interleukin&#x02010;8 (IL&#x02010;8) release from whole blood and IL&#x02010;8 production by human alveolar macrophages</article-title>. <source xml:lang="en">J Antimicrob Chemother</source>. <year>2001</year>;<volume>47</volume>(<issue>6</issue>):<fpage>867</fpage>&#x02010;<lpage>870</lpage>.<pub-id pub-id-type="pmid">11389120</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="rmv2163-cit-0095">
<string-name>
<surname>Sugiyama</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Shirai</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mukae</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells</article-title>. <source xml:lang="en">Clin Exp Immunol</source>. <year>2007</year>;<volume>147</volume>(<issue>3</issue>):<fpage>540</fpage>&#x02010;<lpage>546</lpage>.<pub-id pub-id-type="pmid">17302905</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="rmv2163-cit-0096">
<string-name>
<surname>Iwamoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Azuma</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kumamoto</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Efficacy of azithromycin in preventing lethal graft&#x02010;versus&#x02010;host disease</article-title>. <source xml:lang="en">Clin Exp Immunol</source>. <year>2013</year>;<volume>171</volume>(<issue>3</issue>):<fpage>338</fpage>&#x02010;<lpage>345</lpage>.<pub-id pub-id-type="pmid">23379441</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="rmv2163-cit-0097">
<string-name>
<surname>Iwamoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kumamoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Azuma</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>The effect of azithromycin on the maturation and function of murine bone marrow&#x02010;derived dendritic cells</article-title>. <source xml:lang="en">Clin Exp Immunol</source>. <year>2011</year>;<volume>166</volume>(<issue>3</issue>):<fpage>385</fpage>&#x02010;<lpage>392</lpage>.<pub-id pub-id-type="pmid">22059997</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="rmv2163-cit-0098">
<string-name>
<surname>Lin</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>WI</given-names>
</string-name>, <string-name>
<surname>Kuo</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Hsiao</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>PY</given-names>
</string-name>. <article-title>Effect of azithromycin on natural killer cell function</article-title>. <source xml:lang="en">Int Immunopharmacol</source>. <year>2012</year>;<volume>13</volume>(<issue>1</issue>):<fpage>8</fpage>&#x02010;<lpage>14</lpage>.<pub-id pub-id-type="pmid">22410149</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="rmv2163-cit-0099">
<string-name>
<surname>Yamasawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Oshikawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ohno</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sugiyama</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Macrolides inhibit epithelial cell&#x02010;mediated neutrophil survival by modulating granulocyte macrophage colony&#x02010;stimulating factor release</article-title>. <source xml:lang="en">Am J Respir Cell Mol Biol</source>. <year>2004</year>;<volume>30</volume>(<issue>4</issue>):<fpage>569</fpage>&#x02010;<lpage>575</lpage>.<pub-id pub-id-type="pmid">14551160</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="rmv2163-cit-0100">
<string-name>
<surname>Stamatiou</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Paraskeva</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Boukas</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Gourgoulianis</surname>
<given-names>KI</given-names>
</string-name>, <string-name>
<surname>Molyvdas</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Hatziefthimiou</surname>
<given-names>AA</given-names>
</string-name>. <article-title>Azithromycin has an antiproliferative and autophagic effect on airway smooth muscle cells</article-title>. <source xml:lang="en">Eur Respir J</source>. <year>2009</year>;<volume>34</volume>(<issue>3</issue>):<fpage>721</fpage>&#x02010;<lpage>730</lpage>.<pub-id pub-id-type="pmid">19386688</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="rmv2163-cit-0101">
<string-name>
<surname>Daenas</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hatziefthimiou</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Gourgoulianis</surname>
<given-names>KI</given-names>
</string-name>, <string-name>
<surname>Molyvdas</surname>
<given-names>PA</given-names>
</string-name>. <article-title>Azithromycin has a direct relaxant effect on precontracted airway smooth muscle</article-title>. <source xml:lang="en">Eur J Pharmacol</source>. <year>2006</year>;<volume>553</volume>(<issue>1&#x02013;3</issue>):<fpage>280</fpage>&#x02010;<lpage>287</lpage>.<pub-id pub-id-type="pmid">17070799</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="rmv2163-cit-0102">
<string-name>
<surname>Asgrimsson</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Gudjonsson</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Gudmundsson</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Baldursson</surname>
<given-names>O</given-names>
</string-name>. <article-title>Novel effects of azithromycin on tight junction proteins in human airway epithelia</article-title>. <source xml:lang="en">Antimicrob Agents Chemother</source>. <year>2006</year>;<volume>50</volume>(<issue>5</issue>):<fpage>1805</fpage>&#x02010;<lpage>1812</lpage>.<pub-id pub-id-type="pmid">16641453</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="rmv2163-cit-0103">
<string-name>
<surname>Huang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10223</issue>):<fpage>497</fpage>&#x02010;<lpage>506</lpage>.<pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="rmv2163-cit-0104">
<string-name>
<surname>Imamura</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yanagihara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mizuta</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Azithromycin inhibits MUC5AC production induced by the <italic>Pseudomonas aeruginosa</italic> autoinducer N&#x02010;(3&#x02010;Oxododecanoyl) homoserine lactone in NCI&#x02010;H292 cells</article-title>. <source xml:lang="en">Antimicrob Agents Chemother</source>. <year>2004</year>;<volume>48</volume>(<issue>9</issue>):<fpage>3457</fpage>&#x02010;<lpage>3461</lpage>.<pub-id pub-id-type="pmid">15328111</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="rmv2163-cit-0105">
<string-name>
<surname>Ribeiro</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Hurd</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well&#x02010;differentiated human airway epithelia</article-title>. <source xml:lang="en">PLoS One.</source>
<year>2009</year>;<volume>4</volume>(<issue>6</issue>):<elocation-id>e5806</elocation-id>.<pub-id pub-id-type="pmid">19503797</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="rmv2163-cit-0106">
<string-name>
<surname>Shinkai</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Foster</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Rubin</surname>
<given-names>BK</given-names>
</string-name>. <article-title>Macrolide antibiotics modulate ERK phosphorylation and IL&#x02010;8 and GM&#x02010;CSF production by human bronchial epithelial cells</article-title>. <source xml:lang="en">Am J Physiol Lung Cell Mol Physiol</source>. <year>2006</year>;<volume>290</volume>(<issue>1</issue>):<fpage>L75</fpage>&#x02010;<lpage>L85</lpage>.<pub-id pub-id-type="pmid">16085674</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="rmv2163-cit-0107">
<string-name>
<surname>Wallwork</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Coman</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Mackay&#x02010;Sim</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Greiff</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Cervin</surname>
<given-names>A</given-names>
</string-name>. <article-title>A double&#x02010;blind, randomized, placebo&#x02010;controlled trial of macrolide in the treatment of chronic rhinosinusitis</article-title>. <source xml:lang="en">Laryngoscope</source>. <year>2006</year>;<volume>116</volume>(<issue>2</issue>):<fpage>189</fpage>&#x02010;<lpage>193</lpage>.<pub-id pub-id-type="pmid">16467702</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="rmv2163-cit-0108">
<string-name>
<surname>Yamada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fujieda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mori</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>H</given-names>
</string-name>. <article-title>Macrolide treatment decreased the size of nasal polyps and IL&#x02010;8 levels in nasal lavage</article-title>. <source xml:lang="en">Am J Rhinol</source>. <year>2000</year>;<volume>14</volume>(<issue>3</issue>):<fpage>143</fpage>&#x02010;<lpage>148</lpage>.<pub-id pub-id-type="pmid">10887619</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="rmv2163-cit-0109">
<string-name>
<surname>Rapp</surname>
<given-names>RP</given-names>
</string-name>. <article-title>Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions</article-title>. <source xml:lang="en">Ann Pharmacother</source>. <year>1998</year>;<volume>32</volume>(<issue>7&#x02013;8</issue>):<fpage>785</fpage>&#x02010;<lpage>793</lpage>.<pub-id pub-id-type="pmid">9681095</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="rmv2163-cit-0110">
<string-name>
<surname>Serisier</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases</article-title>. <source xml:lang="en">Lancet Respir Med</source>. <year>2013</year>;<volume>1</volume>(<issue>3</issue>):<fpage>262</fpage>&#x02010;<lpage>274</lpage>.<pub-id pub-id-type="pmid">24429132</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="rmv2163-cit-0111">
<string-name>
<surname>Parnham</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Erakovic Haber</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Giamarellos&#x02010;Bourboulis</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Perletti</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Verleden</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Vos</surname>
<given-names>R</given-names>
</string-name>. <article-title>Azithromycin: mechanisms of action and their relevance for clinical applications</article-title>. <source xml:lang="en">Pharmacol Ther</source>. <year>2014</year>;<volume>143</volume>(<issue>2</issue>):<fpage>225</fpage>&#x02010;<lpage>245</lpage>.<pub-id pub-id-type="pmid">24631273</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="rmv2163-cit-0112">
<string-name>
<surname>Lucchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Damle</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Fang</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin</article-title>. <source xml:lang="en">J Antimicrob Chemother</source>. <year>2008</year>;<volume>61</volume>(<issue>4</issue>):<fpage>884</fpage>&#x02010;<lpage>891</lpage>.<pub-id pub-id-type="pmid">18252692</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="rmv2163-cit-0113">
<string-name>
<surname>Damle</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Vourvahis</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Leaney</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Corrigan</surname>
<given-names>B</given-names>
</string-name>. <article-title>Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID&#x02010;19</article-title>. <source xml:lang="en">Clin Pharmacol Ther</source>. <year>2020</year>;<volume>108</volume>(<issue>2</issue>):<fpage>201</fpage>&#x02010;<lpage>211</lpage>.<pub-id pub-id-type="pmid">32302411</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="rmv2163-cit-0114">
<string-name>
<surname>Cigana</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Assael</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Melotti</surname>
<given-names>P</given-names>
</string-name>. <article-title>Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells</article-title>. <source xml:lang="en">Antimicrob Agents Chemother</source>. <year>2007</year>;<volume>51</volume>(<issue>3</issue>):<fpage>975</fpage>&#x02010;<lpage>981</lpage>.<pub-id pub-id-type="pmid">17210769</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="rmv2163-cit-0115">
<string-name>
<surname>Hua</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>LX</given-names>
</string-name>, et al. <article-title>Rapamycin inhibition of eosinophil differentiation attenuates allergic airway inflammation in mice</article-title>. <source xml:lang="en">Respirology</source>. <year>2015</year>;<volume>20</volume>(<issue>7</issue>):<fpage>1055</fpage>&#x02010;<lpage>1065</lpage>.<pub-id pub-id-type="pmid">26053964</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="rmv2163-cit-0116">
<string-name>
<surname>Ratzinger</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Haslacher</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Poeppl</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>Azithromycin suppresses CD4(+) T&#x02010;cell activation by direct modulation of mTOR activity</article-title>. <source xml:lang="en">Sci Rep</source>. <year>2014</year>;<volume>4</volume>:<elocation-id>7438</elocation-id>.<pub-id pub-id-type="pmid">25500904</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="rmv2163-cit-0117">
<string-name>
<surname>Morinaga</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yanagihara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Miyashita</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Azithromycin, clarithromycin and telithromycin inhibit MUC5AC induction by Chlamydophila pneumoniae in airway epithelial cells</article-title>. <source xml:lang="en">Pulm Pharmacol Ther</source>. <year>2009</year>;<volume>22</volume>(<issue>6</issue>):<fpage>580</fpage>&#x02010;<lpage>586</lpage>.<pub-id pub-id-type="pmid">19716898</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="rmv2163-cit-0118">
<string-name>
<surname>Cigana</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Nicolis</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Pasetto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Assael</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Melotti</surname>
<given-names>P</given-names>
</string-name>. <article-title>Anti&#x02010;inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells</article-title>. <source xml:lang="en">Biochem Biophys Res Commun</source>. <year>2006</year>;<volume>350</volume>(<issue>4</issue>):<fpage>977</fpage>&#x02010;<lpage>982</lpage>.<pub-id pub-id-type="pmid">17045242</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0119"><label>119</label><mixed-citation publication-type="journal" id="rmv2163-cit-0119">
<string-name>
<surname>Yamauchi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Shibata</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kimura</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Azithromycin suppresses interleukin&#x02010;12p40 expression in lipopolysaccharide and interferon&#x02010;gamma stimulated macrophages</article-title>. <source xml:lang="en">Int J Biol Sci</source>. <year>2009</year>;<volume>5</volume>(<issue>7</issue>):<fpage>667</fpage>&#x02010;<lpage>678</lpage>.<pub-id pub-id-type="pmid">19893639</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0120"><label>120</label><mixed-citation publication-type="journal" id="rmv2163-cit-0120">
<string-name>
<surname>Hodge</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hodge</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Jersmann</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>2008</year>;<volume>178</volume>(<issue>2</issue>):<fpage>139</fpage>&#x02010;<lpage>148</lpage>.<pub-id pub-id-type="pmid">18420960</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0121"><label>121</label><mixed-citation publication-type="journal" id="rmv2163-cit-0121">
<string-name>
<surname>Hodge</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hodge</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Brozyna</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jersmann</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Holmes</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Reynolds</surname>
<given-names>PN</given-names>
</string-name>. <article-title>Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages</article-title>. <source xml:lang="en">Eur Respir J</source>. <year>2006</year>;<volume>28</volume>(<issue>3</issue>):<fpage>486</fpage>&#x02010;<lpage>495</lpage>.<pub-id pub-id-type="pmid">16737992</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0122"><label>122</label><mixed-citation publication-type="journal" id="rmv2163-cit-0122">
<string-name>
<surname>Araki</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yanagihara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Morinaga</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Azithromycin inhibits nontypeable <italic>Haemophilus influenzae</italic>&#x02010;induced MUC5AC expression and secretion via inhibition of activator protein&#x02010;1 in human airway epithelial cells</article-title>. <source xml:lang="en">Eur J Pharmacol</source>. <year>2010</year>;<volume>644</volume>(<issue>1&#x02013;3</issue>):<fpage>209</fpage>&#x02010;<lpage>214</lpage>.<pub-id pub-id-type="pmid">20619258</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0123"><label>123</label><mixed-citation publication-type="journal" id="rmv2163-cit-0123">
<string-name>
<surname>Shimizu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Shimizu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hattori</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Gabazza</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Majima</surname>
<given-names>Y</given-names>
</string-name>. <article-title>In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>2003</year>;<volume>168</volume>(<issue>5</issue>):<fpage>581</fpage>&#x02010;<lpage>587</lpage>.<pub-id pub-id-type="pmid">12829454</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0124"><label>124</label><mixed-citation publication-type="journal" id="rmv2163-cit-0124">
<string-name>
<surname>Shao</surname>
<given-names>MX</given-names>
</string-name>, <string-name>
<surname>Nadel</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF&#x02010;alpha&#x02010;converting enzyme</article-title>. <source xml:lang="en">J Immunol</source>. <year>2005</year>;<volume>175</volume>(<issue>6</issue>):<fpage>4009</fpage>&#x02010;<lpage>4016</lpage>.<pub-id pub-id-type="pmid">16148149</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0125"><label>125</label><mixed-citation publication-type="journal" id="rmv2163-cit-0125">
<string-name>
<surname>Park</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>LD</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Chorley</surname>
<given-names>BN</given-names>
</string-name>, <string-name>
<surname>Adler</surname>
<given-names>KB</given-names>
</string-name>. <article-title>Human neutrophil elastase induces hypersecretion of mucin from well&#x02010;differentiated human bronchial epithelial cells in vitro via a protein kinase C{delta}&#x02010;mediated mechanism</article-title>. <source xml:lang="en">Am J Pathol</source>. <year>2005</year>;<volume>167</volume>(<issue>3</issue>):<fpage>651</fpage>&#x02010;<lpage>661</lpage>.<pub-id pub-id-type="pmid">16127146</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0126"><label>126</label><mixed-citation publication-type="journal" id="rmv2163-cit-0126">
<string-name>
<surname>Halldorsson</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gudjonsson</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Gottfredsson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Gudmundsson</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Baldursson</surname>
<given-names>O</given-names>
</string-name>. <article-title>Azithromycin maintains airway epithelial integrity during <italic>Pseudomonas aeruginosa</italic> infection</article-title>. <source xml:lang="en">Am J Respir Cell Mol Biol</source>. <year>2010</year>;<volume>42</volume>(<issue>1</issue>):<fpage>62</fpage>&#x02010;<lpage>68</lpage>.<pub-id pub-id-type="pmid">19372247</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0127"><label>127</label><mixed-citation publication-type="journal" id="rmv2163-cit-0127">
<string-name>
<surname>Shakoory</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Carcillo</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Chatham</surname>
<given-names>WW</given-names>
</string-name>, et al. <article-title>Interleukin&#x02010;1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial</article-title>. <source xml:lang="en">Crit Care Med</source>. <year>2016</year>;<volume>44</volume>(<issue>2</issue>):<fpage>275</fpage>&#x02010;<lpage>281</lpage>.<pub-id pub-id-type="pmid">26584195</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0128"><label>128</label><mixed-citation publication-type="journal" id="rmv2163-cit-0128">
<string-name>
<surname>Xu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Pathological findings of COVID&#x02010;19 associated with acute respiratory distress syndrome</article-title>. <source xml:lang="en">Lancet Respir Med</source>. <year>2020</year>;<volume>8</volume>:<fpage>420</fpage>&#x02010;<lpage>422</lpage>.<pub-id pub-id-type="pmid">32085846</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0129"><label>129</label><mixed-citation publication-type="journal" id="rmv2163-cit-0129">
<string-name>
<surname>Ruan</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>J</given-names>
</string-name>. <article-title>Clinical predictors of mortality due to COVID&#x02010;19 based on an analysis of data of 150 patients from Wuhan</article-title>. <source xml:lang="en">China Intens Care Med</source>. <year>2020</year>;<volume>46</volume>(<issue>5</issue>):<fpage>846&#x02010;848</fpage>
<ext-link ext-link-type="uri" xlink:href="doi:10.1007/s00134-020-05991-x">doi:10.1007/s00134-020-05991-x</ext-link>. </mixed-citation></ref><ref id="rmv2163-bib-0130"><label>130</label><mixed-citation publication-type="miscellaneous" id="rmv2163-cit-0130">
<string-name>
<surname>Liao</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>The landscape of lung bronchoalveolar immune cells in COVID&#x02010;19 revealed by single&#x02010;cell RNA sequencing</article-title>. <italic>bioRxiv</italic>
<year>2020</year>.</mixed-citation></ref><ref id="rmv2163-bib-0131"><label>131</label><mixed-citation publication-type="miscellaneous" id="rmv2163-cit-0131">
<string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Aberrant pathogenic GM&#x02010;CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus</article-title>. <italic>bioRxiv</italic>
<year>2020</year>.</mixed-citation></ref><ref id="rmv2163-bib-0132"><label>132</label><mixed-citation publication-type="journal" id="rmv2163-cit-0132">
<collab collab-type="authors">RECOVERY Collaborative Group</collab>
, <string-name>
<surname>Horby</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>WS</given-names>
</string-name>, et al. <article-title>Dexamethasone in hospitalized patients with Covid&#x02010;19&#x02014;preliminary report</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>;NEJMoa2021436. <ext-link ext-link-type="uri" xlink:href="doi:10.1056/NEJMoa2021436">doi:10.1056/NEJMoa2021436</ext-link>.</mixed-citation></ref><ref id="rmv2163-bib-0133"><label>133</label><mixed-citation publication-type="journal" id="rmv2163-cit-0133">
<string-name>
<surname>Cavalcanti</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Zampieri</surname>
<given-names>FG</given-names>
</string-name>, <string-name>
<surname>Rosa</surname>
<given-names>RG</given-names>
</string-name>, et al. <article-title>Hydroxychloroquine with or without azithromycin in mild&#x02010;to&#x02010;moderate Covid&#x02010;19</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>;NEJMoa2019014. <ext-link ext-link-type="uri" xlink:href="doi:10.1056/NEJMoa2019014">doi:10.1056/NEJMoa2019014</ext-link>. </mixed-citation></ref><ref id="rmv2163-bib-0134"><label>134</label><mixed-citation publication-type="journal" id="rmv2163-cit-0134">
<string-name>
<surname>Hinks</surname>
<given-names>TSC</given-names>
</string-name>, <string-name>
<surname>Barber</surname>
<given-names>VS</given-names>
</string-name>, <string-name>
<surname>Black</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>A multi&#x02010;centre open&#x02010;label two&#x02010;arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID&#x02010;19: study protocol for the ATOMIC2 trial</article-title>. <source xml:lang="en">Trials</source>. <year>2020</year>;<volume>21</volume>(<issue>1</issue>):<elocation-id>718</elocation-id>.<pub-id pub-id-type="pmid">32807209</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0135"><label>135</label><mixed-citation publication-type="journal" id="rmv2163-cit-0135">
<string-name>
<surname>Hansen</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>McCullough</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Adverse events in people taking macrolide antibiotics versus placebo for any indication</article-title>. <source xml:lang="en">Cochrane Database Syst Rev</source>. <year>2019</year>;<volume>1</volume>:<elocation-id>CD011825</elocation-id>.<pub-id pub-id-type="pmid">30656650</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0136"><label>136</label><mixed-citation publication-type="journal" id="rmv2163-cit-0136">
<string-name>
<surname>Yanagihara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Izumikawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Higa</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Efficacy of azithromycin in the treatment of community&#x02010;acquired pneumonia, including patients with macrolide&#x02010;resistant <italic>Streptococcus pneumoniae</italic> infection</article-title>. <source xml:lang="en">Intern Med</source>. <year>2009</year>;<volume>48</volume>(<issue>7</issue>):<fpage>527</fpage>&#x02010;<lpage>535</lpage>.<pub-id pub-id-type="pmid">19336954</pub-id></mixed-citation></ref><ref id="rmv2163-bib-0137"><label>137</label><mixed-citation publication-type="journal" id="rmv2163-cit-0137">
<string-name>
<surname>Jakobsson</surname>
<given-names>HE</given-names>
</string-name>, <string-name>
<surname>Jernberg</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Andersson</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Sjolund&#x02010;Karlsson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jansson</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Engstrand</surname>
<given-names>L</given-names>
</string-name>. <article-title>Short&#x02010;term antibiotic treatment has differing long&#x02010;term impacts on the human throat and gut microbiome</article-title>. <source xml:lang="en">PLoS One.</source>
<year>2010</year>;<volume>5</volume>(<issue>3</issue>):<elocation-id>e9836</elocation-id>.<pub-id pub-id-type="pmid">20352091</pub-id></mixed-citation></ref></ref-list></back></article>